{"aid": "40059388", "title": "Effects of Creatine Supplementation on Brain Function and Health (2022)", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8912287/", "domain": "nih.gov", "votes": 1, "user": "aurareturn", "posted_at": "2024-04-17 01:22:41", "comments": 0, "source_title": "Effects of Creatine Supplementation on Brain Function and Health", "source_text": "Effects of Creatine Supplementation on Brain Function and Health - PMC\n\nSkip to main content\n\nAn official website of the United States government\n\nThe .gov means it\u2019s official. Federal government websites often end in .gov or\n.mil. Before sharing sensitive information, make sure you\u2019re on a federal\ngovernment site.\n\nThe site is secure. The https:// ensures that you are connecting to the\nofficial website and that any information you provide is encrypted and\ntransmitted securely.\n\nLog in\n\n#### Account\n\nLogged in as: username\n\n  * Dashboard\n  * Publications\n  * Account settings\n  * Log out\n\nAccess keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation\n\nPreview improvements coming to the PMC website in October 2024. Learn More or\nTry it out now.\n\n  * Advanced Search\n  * User Guide\n\n  * Journal List\n  * Nutrients\n  * PMC8912287\n\nAs a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: PMC Disclaimer | PMC Copyright Notice\n\nNutrients. 2022 Mar; 14(5): 921.\n\nPublished online 2022 Feb 22. doi: 10.3390/nu14050921\n\nPMCID: PMC8912287\n\nPMID: 35267907\n\n# Effects of Creatine Supplementation on Brain Function and Health\n\nScott C. Forbes,^1,^2 Dean M. Cordingley,^3,^4 Stephen M. Cornish,^2,^3,^5\nBruno Gualano,^6 Hamilton Roschel,^6 Sergej M. Ostojic,^7,^8 Eric S. Rawson,^9\nBrian D. Roy,^10 Konstantinos Prokopidis,^11 Panagiotis Giannos,^12 and Darren\nG. Candow^13,^*\n\n### Scott C. Forbes\n\n^1Department of Physical Education Studies, Faculty of Education, Brandon\nUniversity, Brandon, MB R7A 6A9, Canada; ac.unodnarb@ssebrof\n\n^2Centre for Aging, University of Manitoba, Winnipeg, MB R3T 2N2, Canada;\nac.abotinamu@hsinroc.nehpets\n\nFind articles by Scott C. Forbes\n\n### Dean M. Cordingley\n\n^3Applied Health Sciences, University of Manitoba, Winnipeg, MB R3T 2N2,\nCanada; ac.abotinamuym@didrocmu\n\n^4Pan Am Clinic Foundation, 75 Poseidon Bay, Winnipeg, MB R3M 3E4, Canada\n\nFind articles by Dean M. Cordingley\n\n### Stephen M. Cornish\n\n^2Centre for Aging, University of Manitoba, Winnipeg, MB R3T 2N2, Canada;\nac.abotinamu@hsinroc.nehpets\n\n^3Applied Health Sciences, University of Manitoba, Winnipeg, MB R3T 2N2,\nCanada; ac.abotinamuym@didrocmu\n\n^5Faculty of Kinesiology and Recreation Management, University of Manitoba,\nWinnipeg, MB R3T 2N2, Canada\n\nFind articles by Stephen M. Cornish\n\n### Bruno Gualano\n\n^6Applied Physiology & Nutrition Research Group, Rheumatology Division, School\nof Physical Education and Sport, Faculdade de Medicina FMUSP, Universidade de\nSao Paulo, Sao Paulo 01246-903, Brazil; rb.psu@onalaug (B.G.); rb.psu@srah\n(H.R.)\n\nFind articles by Bruno Gualano\n\n### Hamilton Roschel\n\n^6Applied Physiology & Nutrition Research Group, Rheumatology Division, School\nof Physical Education and Sport, Faculdade de Medicina FMUSP, Universidade de\nSao Paulo, Sao Paulo 01246-903, Brazil; rb.psu@onalaug (B.G.); rb.psu@srah\n(H.R.)\n\nFind articles by Hamilton Roschel\n\n### Sergej M. Ostojic\n\n^7Department of Nutrition and Public Health, University of Agder, 4604\nKristiansand, Norway; on.aiu@cijotso.jegres\n\n^8Applied Bioenergetics Lab, Faculty of Sport and PE, University of Novi Sad,\n21000 Novi Sad, Serbia\n\nFind articles by Sergej M. Ostojic\n\n### Eric S. Rawson\n\n^9Department of Health, Nutrition, and Exercise Science, Messiah University,\nMechanicsburg, PA 17055, USA; ude.haissem@nosware\n\nFind articles by Eric S. Rawson\n\n### Brian D. Roy\n\n^10Department of Kinesiology, Brock University, St. Catharines, ON L2S 3A1,\nCanada; ac.ukcorb@yorb\n\nFind articles by Brian D. Roy\n\n### Konstantinos Prokopidis\n\n^11Department of Musculoskeletal Biology, Institute of Life Course and Medical\nSciences, University of Liverpool, Liverpool L73 FAK, UK;\nku.ca.looprevil@sidipokorp\n\nFind articles by Konstantinos Prokopidis\n\n### Panagiotis Giannos\n\n^12Department of Life Sciences, Faculty of Natural Sciences, Imperial College\nLondon, London SW7 2AZ, UK; ku.ca.lairepmi@91sonnaig.sitoiganap\n\nFind articles by Panagiotis Giannos\n\n### Darren G. Candow\n\n^13Faculty of Kinesiology and Health Studies, University of Regina, Regina, SK\nS4S 0A2, Canada\n\nFind articles by Darren G. Candow\n\nCorinne Joffre, Academic Editor\n\nAuthor information Article notes Copyright and License information PMC\nDisclaimer\n\n^1Department of Physical Education Studies, Faculty of Education, Brandon\nUniversity, Brandon, MB R7A 6A9, Canada; ac.unodnarb@ssebrof\n\n^2Centre for Aging, University of Manitoba, Winnipeg, MB R3T 2N2, Canada;\nac.abotinamu@hsinroc.nehpets\n\n^3Applied Health Sciences, University of Manitoba, Winnipeg, MB R3T 2N2,\nCanada; ac.abotinamuym@didrocmu\n\n^4Pan Am Clinic Foundation, 75 Poseidon Bay, Winnipeg, MB R3M 3E4, Canada\n\n^5Faculty of Kinesiology and Recreation Management, University of Manitoba,\nWinnipeg, MB R3T 2N2, Canada\n\n^6Applied Physiology & Nutrition Research Group, Rheumatology Division, School\nof Physical Education and Sport, Faculdade de Medicina FMUSP, Universidade de\nSao Paulo, Sao Paulo 01246-903, Brazil; rb.psu@onalaug (B.G.); rb.psu@srah\n(H.R.)\n\n^7Department of Nutrition and Public Health, University of Agder, 4604\nKristiansand, Norway; on.aiu@cijotso.jegres\n\n^8Applied Bioenergetics Lab, Faculty of Sport and PE, University of Novi Sad,\n21000 Novi Sad, Serbia\n\n^9Department of Health, Nutrition, and Exercise Science, Messiah University,\nMechanicsburg, PA 17055, USA; ude.haissem@nosware\n\n^10Department of Kinesiology, Brock University, St. Catharines, ON L2S 3A1,\nCanada; ac.ukcorb@yorb\n\n^11Department of Musculoskeletal Biology, Institute of Life Course and Medical\nSciences, University of Liverpool, Liverpool L73 FAK, UK;\nku.ca.looprevil@sidipokorp\n\n^12Department of Life Sciences, Faculty of Natural Sciences, Imperial College\nLondon, London SW7 2AZ, UK; ku.ca.lairepmi@91sonnaig.sitoiganap\n\n^13Faculty of Kinesiology and Health Studies, University of Regina, Regina, SK\nS4S 0A2, Canada\n\n^*Correspondence: ac.anigeru@wodnac.nerrad; Tel.: +1-306-209-0280\n\nReceived 2022 Jan 27; Accepted 2022 Feb 17.\n\nCopyright \u00a9 2022 by the authors.\n\nLicensee MDPI, Basel, Switzerland. This article is an open access article\ndistributed under the terms and conditions of the Creative Commons Attribution\n(CC BY) license (https://creativecommons.org/licenses/by/4.0/).\n\nGo to:\n\n## Abstract\n\nWhile the vast majority of research involving creatine supplementation has\nfocused on skeletal muscle, there is a small body of accumulating research\nthat has focused on creatine and the brain. Preliminary studies indicate that\ncreatine supplementation (and guanidinoacetic acid; GAA) has the ability to\nincrease brain creatine content in humans. Furthermore, creatine has shown\nsome promise for attenuating symptoms of concussion, mild traumatic brain\ninjury and depression but its effect on neurodegenerative diseases appears to\nbe lacking. The purpose of this narrative review is to summarize the current\nbody of research pertaining to creatine supplementation on total creatine and\nphophorylcreatine (PCr) content, explore GAA as an alternative or adjunct to\ncreatine supplementation on brain creatine uptake, assess the impact of\ncreatine on cognition with a focus on sleep deprivation, discuss the effects\nof creatine supplementation on a variety of neurological and mental health\nconditions, and outline recent advances on creatine supplementation as a\nneuroprotective supplement following traumatic brain injury or concussion.\n\nKeywords: supplementation, mental health, depression, amino acids\n\nGo to:\n\n## 1\\. Introduction\n\nThe brain is a highly energetic complex organ, consuming approximately 20% of\ntotal resting energy despite accounting for only about 2% of total body mass\n[1]. Neurons require a constant supply of adenosine triphosphate (ATP) for\nseveral cellular processes, including maintaining ion gradients,\nneurotransmitter exocytosis, and synaptic functioning [2]. Creatine, a\nnitrogenous organic compound derived from reactions involving the amino acids\narginine, glycine, and methionine, is important for resynthesizing ATP,\nparticularly during times of increased metabolic demand (e.g., sleep\ndeprivation, mental health conditions, or neurological diseases) [3,4,5].\nThrough the reversible reaction catalyzed by creatine kinase,\nphophorylcreatine (PCr) combines with adenosine diphosphate (ADP) to\nresynthesize ATP [6]. PCr functions as a high-energy molecule capable of\nresynthesizing ATP significantly faster than oxidative phosphorylation and\nglycolytic processes [6,7].\n\nWhile the vast majority of creatine is synthesized in the kidneys and liver,\ncreatine can also be endogenously synthesized in the brain [8,9,10].\nFurthermore, creatine has some ability to cross the blood\u2013brain barrier (BBB;\nvia microcapillary endothelial cells expressing the creatine transporter\nSLC6A8) [8] and accumulate in the brain. However, creatine uptake in the brain\nis typically limited in relation to other tissues such as skeletal muscle,\npossibly because of low permeability of the BBB to creatine and/or astrocytes\nlack the expression of SLC6A8 [8]. Therefore, total creatine ingestion may\nneed to be higher or for longer periods of time to produce significant effects\nin the brain compared to skeletal muscle. Over the past few years, there has\nbeen an emergence of research investigating the impact of creatine\nsupplementation on a variety of conditions that may be influenced by impaired\nor altered brain bioenergetics [5].\n\nThe purpose of this narrative review is to summarize the current body of\nresearch pertaining to creatine supplementation on total creatine and PCr\ncontent, explore guanidinoacetic acid (GAA; a creatine precursor) as an\nalternative or adjunct to creatine supplementation on brain creatine uptake,\nassess the impact of creatine on cognition with a focus on sleep deprivation,\ndiscuss the effects of creatine supplementation on a variety of neurological\nand mental health conditions, and outline recent advances on creatine\nsupplementation as a neuroprotective supplement following traumatic brain\ninjury or concussions.\n\nGo to:\n\n## 2\\. Creatine and Guanidinoacetic Acid (GAA) Supplementation on Brain\nCreatine and Phophorylcreatine (PCr)\n\n### 2.1. Creatine Monohdyrate Supplementation\n\nPioneering work in the 1990s by Harris et al. [9] and Hultman et al. [10]\ndemonstrated increased muscle creatine levels following oral creatine\nmonohydrate supplementation. Since the publication of these studies, it has\nbeen repeatedly shown that creatine supplementation increases muscle creatine\nand PCr levels using both nuclear magnetic resonance (NMR) spectroscopy and\nmuscle biopsies (reviewed in Kreider et al. [11]). It appears that the average\nincrease in muscle creatine from creatine supplementation is about 20% with\nresponses that could be characterized as low, medium, or high (\u224840%).\nIntramuscular creatine levels can be further increased when creatine\nmonohydrate ingestion is combined with exercise [9,12], insulin [13],\ncarbohydrate [14], carbohydrate and protein [15], or lipoic acid [16].\n\nThere is a plethora of research which has examined the effects of creatine\nsupplementation on skeletal muscle creatine levels, muscle mass and function\n(e.g., sports performance, strength, resistance to fatigue, adaptation to\nexercise training). However, research is very limited regarding the efficacy\nof creatine supplementation on brain creatine and brain function (e.g.,\ncognitive processing, recovery from brain injury) (reviewed in [5,17,18]).\n\nDolan et al. [18] recently reviewed the effects of creatine supplementation on\nbrain creatine and several observations can be made from that analysis and the\noriginal articles. Across 12 individual studies reported in 11 articles, brain\ncreatine content changed from \u22120.7% to 14.6%, with the majority of studies (n\n= 10) reporting a 3% to 10% increase [19,20,21,22,23,24,25,26]. However,\nWilkinson et al. [27] and Merege-Filho et al. [28] reported no increase in\nbrain creatine from creatine supplementation. Furthermore, there are some\nreports of no change (\u22120.7%) [24] or decreased brain PCr (\u22123.1%) [20] from\ncreatine supplementation. Brain creatine was derived using proton or\nphosphorous nuclear magnetic resonance spectroscopy (H^1-NMR or P^31-NMR,\nrespectively), in the aforementioned studies. Independent of methodological\ndifferences across studies, this small body of research indicates that\ncreatine supplementation has the ability to increase brain creatine levels,\nbut the magnitude of change is likely less than what is observed in skeletal\nmuscle. There are several possible explanations for the discrepancy between\ncreatine uptake in the brain and skeletal muscle. Skeletal muscle does not\nhave the ability to synthesize creatine. Although >95% of the body\u2019s creatine\nis stored in skeletal muscle, creatine is manufactured in other tissues (e.g.,\nliver, pancreas, kidneys), enters systemic circulation and gains entry into\nskeletal muscle via SLC6A8. Dietary creatine (includes supplementation) gains\nentry into skeletal muscle through the same process. However, the brain has\nthe ability to synthesize creatine [29,30] and therefore appears to be more\nresistant to the uptake of creatine. Indeed, the absence of SLC6A8 in\nastrocytes may limit exogenous brain creatine uptake [31]. It could be that\nthe brain relies primarily on endogenous creatine synthesis until there is\nsome sort of challenge to brain creatine status. These challenges, which could\ncause a decrease in brain creatine could be acute (e.g., sleep deprivation,\nintense exercise) or chronic (e.g., aging, traumatic brain injury, depression,\nAlzheimer\u2019s disease, creatine synthesis enzyme deficiencies). As an example,\nin the case of children with disorders of creatine synthesis, creatine\nsupplementation results in [32,33,34] both clinical improvement and\nnormalization of brain and body creatine levels.\n\nOverall, it appears that brain creatine content can be increased with creatine\nsupplementation. However, it is difficult to compare individual studies where\nbrain creatine was assessed pre- and post-supplementation because the\nsupplementation protocols are heterogeneous (2 to 20 g/d), the populations are\ndifferent (e.g., patient vs. healthy), the regions of the brain assessed were\ndissimilar, and while some labs measure brain PCr using P^31-NMR other\nresearch teams measured total creatine using H^1-NMR. One factor that must be\ninvestigated in the future is the optimal dosage of creatine needed to elicit\nthe largest increase in brain uptake in response to supplementation.\nSimilarly, few data assessing simultaneous changes in creatine in multiple\ntissues (e.g., muscle and brain) are available. It is unlikely that the\naddition of nutrients such as carbohydrate or protein, or endocrine factors\nsuch as insulin will have any effect on brain creatine uptake. Currently,\nresearch indicates that brain creatine increases in response to creatine\nmonohydrate supplementation. This increase is smaller than the skeletal muscle\nresponse to a similar supplementation protocol.\n\n### 2.2. GAA Supplementation\n\nBeing a direct natural precursor of creatine, GAA (also known as glycocyamine;\nchemical formula: C_3H_7N_3O_2) has been used to treat neurological diseases\nfor almost 70 years. In 1952, Henry Borsook from Caltech was arguably the\nfirst to investigate the effects of supplemental GAA (co-administered with\nbetaine) in poliomyelitis-related disability [35]. The authors reported\nbeneficial effects of glycocyamine therapy in patients affected by acute\nanterior poliomyelitis, with the presumed therapeutic mechanism entailing\nenhanced creatine synthesis in target organs, including the brain and skeletal\nmuscle. Succeeding neurological studies from the 1950s derived equivocal\nresults in terms of GAA therapeutic potential, with some showing no clinical\nimprovement in patients with various neurological dysfunctions (e.g., multiple\nsclerosis, amyotrophic lateral sclerosis, Parkinson\u2019s disease) [36,37], while\nothers demonstrated favorable effects of GAA on specific surrogate indicators\nof tissue metabolism in poliomyelitis [38], or mild patient-reported benefits\nfrom the treatment in motor-neuron disease [39]. However, these pioneering\nstudies did not assess the effects of GAA on tissue creatine levels nor did\nthey evaluate more brain-specific outcomes following GAA administration.\n\nA pivotal pre-clinical trial about supplemental GAA and brain metabolism\noriginates from Robert Bertolo\u2019s lab, with his group being the first to\ndemonstrate increased cerebral creatine levels after GAA ingestion [40]. The\nauthors reported that 3-month-old Yucatan miniature pigs, who were fed\ncontrol, GAA- or creatine-supplemented diets for up to 19 days, experienced a\nmodest rise in brain creatine (determined with a brain biopsy), with the\nmagnitude tending to be superior in animals fed with GAA compared to controls\nand creatine-fed pigs. In addition, hepatic, muscle, and kidney creatine\nlevels were higher with GAA versus creatine supplementation. The above\nfindings are corroborated in a randomized controlled crossover trial with\nhealthy men [41], where 28 days of GAA supplementation (3 g/day) resulted in a\nsignificant elevation (up to 16.2%) in brain creatine levels assessed via\nmagnetic resonance (MR) spectroscopy in the middle cerebellar peduncle and\nparacentral grey matter, with the rise greater compared to creatine. The\ncapacity of GAA to increase creatine levels using MR spectroscopy across the\nhuman brain was confirmed in several trials [42,43], with published data\nsuggesting a favorable (and brain location-specific) response rate to short-\nterm GAA loading in human cohorts [44]. Besides amplifying cerebral creatine\nconcentrations, GAA (sole or co-administered with creatine) can positively\naffect several brain performance outcomes, including specific domains of\nmemory in Yucatan miniature pigs [45], or patient- and clinician-reported\nindices of everyday performance in women with chronic fatigue syndrome [46],\nand older men and women [47]. Favorable effects of GAA might be due to its\nrole in the control and provision of cellular energy, including its\ninteraction with cellular transporters for taurine and gamma-aminobutyric\nacid, previously dismissed as un-targetable carriers by other bioenergetics\ntherapeutics (including creatine) (for a detailed review, see [48]).\n\nBesides its direct role in creatine biosynthesis, GAA might impact brain\nfunction via several alternative mechanisms reported in animal studies.\nTakahashi and co-workers [49] investigated possible neuropharmacological\neffects of GAA in the mammalian brain, demonstrating its impact on modulating\ncerebral cortex electrophysiology. In line with this, GAA application appears\nto induce electrophysiological responses of neurons in primary culture and\nacute murine brain slices [50]. The research group of Angela Wyss from the\nFederal University of Rio Grande do Sul extensively investigated intra-\ncerebral administration of GAA in various milieux and revealed that exogenous\nGAA could repress the activities of several energy-related pathways and\nenzymes, including Na^+/K^+-ATPase [51], creatine kinase [52], and the\nrespiratory chain [53]. Intra-striatal GAA also inhibits glutamate uptake\n[54], increases acetylcholinesterase activity [55], and decreases antioxidant\ndefense [56], suggesting additional energy-independent roles of exogenous GAA\nin animal brains. The above effects might be of little relevance to humans\nsince GAA supplementation likely drives no GAA accumulation in the brain of\nhealthy men [57]. Animal studies typically administered GAA in dosages at\nleast two orders of magnitude higher than those used in human nutritional\nstudies. However, supplemental GAA tends to decrease brain choline and\nglutamate concentrations in healthy men [42,57]; the consequences of these\nmetabolic perturbations (although marginal) for brain health are currently\nunknown and require further assessment.\n\nPreliminary data from human studies suggest that GAA can raise brain creatine\nlevels and improve brain performance, with GAA (supplemented alone or along\nwith creatine) perhaps put forward as a promising dietary strategy that could\nalter biomarkers of tissue bioenergetics in the brain. Nevertheless, more\nwell-designed longitudinal studies are warranted to examine the brain-boosting\npotential of GAA in various clinical environments, including disorders with\nneurocognitive impairment and white matter diseases. While future efficacy\nstudies with GAA for brain health are eagerly expected, GAA safety trials\nremain our utmost priority, considering possible neurotoxicity of exogenous\namino acids and derivatives [58]. Addressing both the safety and efficacy of\nsupplemental GAA and other open questions of GAA utilization in nutritional\nneuroscience (Figure 1) might be the next step forward for the creatine\nresearch.\n\nOpen in a separate window\n\nFigure 1\n\nOpen questions of guanidinoacetic acid (GAA) supplementation for brain health.\n\nGo to:\n\n## 3\\. Creatine and Cognitive Function\n\nRobust evidence that clearly demonstrates the importance of creatine on\ncognitive function comes from individuals with creatine deficient syndromes,\nknown to deplete brain creatine stores. Creatine deficiency syndrome is\ncharacterized by mental and development disorders such as learning delays and\nseizures [59,60], and importantly these symptoms are reversed, at least in\npart, by creatine supplementation [32,34,61]. In humans, there are mixed\nresults, with some studies finding some benefits on cognitive functioning\n[23,62,63,64,65,66,67,68,69,70,71,72], while others found no effect\n[28,73,74], as recently reviewed by Roschel and colleagues [5]. Similar to\ncognitive function, research is mixed regarding the effectiveness of creatine\nsupplementation on improving measures of memory. In aging adults (68\u201385 years)\ncreatine supplementation (20 g/day for 7 days) improved measures of memory\n(forward number recall, backward and forward spatial recall, and long-term\nmemory) [72]. Rae et al. [75] found improvements in working memory following\ncreatine supplementation (5 g/day for 6 weeks) in vegetarians. In a direct\ncomparison of omnivores and vegetarians, Benton and Donohoe [71] found better\nmemory following creatine supplementation (20 g/day for 5 days) in vegetarians\nrelative to meat eaters. However, others have failed to find beneficial\neffects from creatine supplementation on measures of memory in children [28],\nadults [23,65,66,73] and older adults [72,74].\n\nSleep deprivation is known to impact brain bioenergetics, and it appears that\nthe effects of creatine supplementation in combination with sleep deprivation\nmay enhance cognitive function compared to placebo. However, presently there\nare only two studies that have investigated cognitive function following sleep\ndeprivation in humans and both were combined with mild to moderate exercise\n[65,66]. For example, following 24 h of sleep deprivation, creatine\nsupplementation resulted in less change in performance from baseline in random\nmovement generation, choice reaction time, balance and mood state [66].\nFurthermore, in a similar experiment by the same group, creatine\nsupplementation attenuated the sleep-deprived loss of complex central\nexecutive function [65].\n\nOverall, there is some evidence that creatine supplementation can augment\nmeasures of cognitive function. These cognitive effects appear to be more\nrobust when brain bioenergetics are challenged, such as sleep deprivation.\n\nGo to:\n\n## 4\\. Creatine for Neurodegenerative Diseases\n\nThe relevance of the adenosine triphosphate (ATP)/creatine kinase (CK)/PCr\nsystem for central nervous system (CNS) homeostasis is widely recognized.\nTherefore, increasing brain creatine content is thought to be potentially\nbeneficial for different clinical conditions, such as neurodegenerative\ndiseases [5,76]. Neurodegenerative diseases are commonly characterized as\nconditions involving a progressive and irreversible loss of neuronal function,\nthus hampering the ability to perform both cognitive and/or motor tasks. In\nlight of the possible effects of creatine on muscle strength, mass and\nfunctionality, its consideration as an adjunct therapy to mitigate disease-\nrelated physical impairments is warranted [76,77].\n\nAdditionally, oxidative stress, energy depletion and mitochondrial damage are\ncommon features in neurodegenerative diseases, to which creatine may act by\npossibly scavenging reactive oxygen species and increasing energy production\n[78,79]. This section will highlight the impact of creatine on a variety of\nneurological diseases.\n\n### 4.1. Amyotrophic Lateral Sclerosis\n\nAmyotrophic lateral sclerosis (ALS) is a neurodegenerative disease\ncharacterized by the progressive loss of motor neurons, resulting in muscle\natrophy, weakness and paralysis, ultimately leading to death [6]. Using\ncreatine in ALS resides in its potential role as a neuroprotective agent,\nreducing oxidative stress, attenuating mitochondrial damage and dysfunction\nand generating energy through ATP resynthesis [78,80].\n\nDespite preliminary evidence in probable/definite ALS patients showing that\ncreatine supplementation resulted in improved physical performance and reduced\nmuscle fatigue [81], other studies in ALS patients with more advanced disease\nsymptoms did not corroborate these findings [82,83,84]. Therefore, the\nclinical use of creatine in ALS lacks proper empirical support.\n\n### 4.2. Duchenne Muscular Dystrophy\n\nDuchenne muscular dystrophy (DMD) is a life-threatening disease caused by\nmutations in the dystrophin gene that significantly reduces life span, mainly\ndue to either respiratory or cardiac failure [85].\n\nCreatine supplementation has been shown to improve strength and time to\nexhaustion in DMD and young Becker\u2019s muscular dystrophy patients [86]. The\nsame authors also found improved bone mineral density among the subgroup of\npatients able to walk during the trial. These results were further\ncorroborated after a 4-month cross-over trial with creatine supplementation\nshowing improvements in handgrip strength and fat-free mass in DMD patients\n[87] and a trend towards greater improvement in strength and functionality in\nDMD [88].\n\nIndeed, results are promising, and more research is warranted to further\nunderstand the effects of creatine in DMD and other muscular dystrophies.\nImportantly, creatine supplementation may confer different effects among the\ndifferent forms of muscle dystrophies, and results with DMD are not directly\ngeneralized to other types of dystrophies.\n\n### 4.3. Huntington\u2019s Disease\n\nHuntington\u2019s disease (HD) is a progressive autosomal dominant\nneurodegenerative condition characterized by movement, cognition, and\nbehavioral impairments, that can also be fatal. It also encompasses\nmitochondrial damage and energy metabolism impairment, that can result in\nincreased brain lactate and reduced ATP and PCr regeneration, owing to\ncreatine as a possible promising therapeutic strategy [78,89].\n\nIn fact, creatine supplementation has been shown to attenuate disease\nprogression [90]; however, these results are not consistent [91,92]. Two other\nstudies showed that creatine supplementation was able to reduce markers of\noxidative injury to DNA, although not accompanied by motor or cognitive\nimprovements [89,93]. More recent evidence [94], with a larger cohort of\npatients with HD followed for 2 years, showed that a 40 g daily dose of\ncreatine supplementation was unable to positively affect the course of the\ndisease. In summary, results across studies render insufficient scientific\nsupport for the use of creatine in this condition.\n\n### 4.4. Multiple Sclerosis\n\nMultiple sclerosis (MS) is characterized as an autoimmune neurodegenerative\ndisease that results in impaired nerve transmission, with symptoms varying\nacross muscle weakness, vision and balance impairments and fatigue. Patients\nwith MS also show alterations in brain and cardiac creatine metabolism,\nfurther warranting studies on the effects of creatine supplementation in this\ndisease.\n\nNonetheless, the few studies performed do not support the use of creatine in\nthis population, as they showed that creatine supplementation did not increase\nmuscle creatine stores [95] nor exercise capacity or muscle power [95,96].\n\n### 4.5. Parkinson\u2019s Disease\n\nParkinson\u2019s disease (PD) is a one of the most common neurodegenerative\ndiseases, especially in older adults. It is characterized by progressive\nlosses of dopaminergic neurons, resulting in both cognitive and motor\nimpairment, with symptoms ranging from tremor, postural instability,\nbradykinesia to loss of muscle mass and strength and increased susceptibility\nto fatigue [97].\n\nAnimal studies have shown that creatine supplementation could be potentially\nneuroprotective by preventing losses of dopaminergic neurons [98]. In humans,\ncreatine has been shown to elicit an improved response to dopaminergic therapy\n[99] and increased strength and muscle function [100]. Additionally, a 10-g\ndaily dose of creatine has been shown to reduce scores on a disease-specific\nevaluation scale (Unified Parkinson\u2019s Disease Rating Scale, UPDRS) after 1\nyear of intervention, suggesting that creatine was able to reduce disease\nprogression. The same consort of investigators observed, however, that disease\nprogression was not different between creatine and placebo groups when follow-\nup was extended and deemed creatine ultimately ineffective to contain disease\nprogression [101].\n\nFurther studies are warranted in order to determine whether creatine, in\nassociation or not with exercise and/or other drugs and dietary supplements,\nmay be beneficial for patients with PD.\n\nIn summary, creatine supplementation appears to have limited, if any, clinical\neffect on the progression or management of neurodegenerative diseases. An\nimportant scientific challenge that remains in this research area is to\ndetermine the optimal creatine supplementation protocol able to increase (or\nreplenish) brain creatine content in order to better understand the\ntherapeutic role of creatine supplementation in neurodegenerative diseases.\n\nGo to:\n\n## 5\\. Creatine and Mental Health\n\nThe prevalence of mental health disorders is well documented through\nepidemiological and survey data. An estimated 26\u201330% of the United States\npopulation is affected by a mental health disorder annually [102], while\nrecent data using the 2012 Canadian Community Health Survey suggests that the\noverall prevalence of mental health disorders in those over 15 years of age\nwas 9.59% [103]. The high prevalence of these disorders and the relatively low\nadherence rates [104], and limited treatment success with medications for some\nconditions [105,106], contributes to a substantial economic impact on society\n[107]. The two most prevalent mental health disorders are depression and\ngeneralized anxiety disorder [103].\n\nThe critical role of creatine in the brain is well documented through creatine\ndeficiency syndromes, which are characterized by intellectual disability,\nlanguage delay, seizure disorders, autism spectrum disorder and various\nmovement disorders, with the primary treatment being creatine monohydrate\nsupplementation in an attempt to increase creatine content in the brain [108].\nMany mental health disorders have also been characterized to have\nabnormalities in brain bioenergetics, with some of the more prevalent\ndisorders, such as depression, being associated with low creatine levels in\ncertain regions of the brain [109]. Based on such observations, there has been\ngrowing interest in the possible use of creatine monohydrate in various\nbrain/neurological disorders, including mental/psychiatric disorders. The\npotential therapeutic use of creatine, possible mechanisms of action, and\nhypothesized clinical implications for psychiatric disorders has been\nextensively reviewed previously [110].\n\n### 5.1. Depression\n\nPopulation-based research has established a link between dietary intake of\ncreatine and depression risk in adults [111]. The authors used the National\nHealth and Nutrition Examination Survey to demonstrate a significant negative\nrelationship between dietary creatine and depression. Direct interventional\nstudies using ^1H-magnetic resonance spectroscopy (^1H-MRS) have also\ndemonstrated that lower creatine levels in the prefrontal cortex are\nassociated with low mood/increased depression [109]. Even prior to these\nobservations, many different groups have undertaken trials of creatine\nsupplementation in both animals and humans alone and/or in combination with\nother pharmaceutical interventions to treat depression.\n\nAnimal research suggests there may be a sex-dependent relationship regarding\ncreatine and depression [110,112,113,114]. Dietary creatine appears to be more\nefficacious in female rats compared to male rats [110,112]; however, creatine\nin combination with other antidepressant drugs does appear to have some\nbenefit in male rodents [114]. The use of creatine has also been investigated\nin other clinical models where depression is often observed as a secondary\nconsequence of disease, or it results from the treatment. For example, in a\nmouse model of epilepsy, dietary creatine treatment not only attenuated\nseizure severity, but it also reduced depressive-like behaviors [115].\nCreatine has also been shown to have anti-depressant effects in amyloid \u03b2_1-40\ntreated mice, a model of Alzheimer\u2019s disease related depression [116]. Chronic\ncorticosterone treatment has also been associated with morphological and\nbehavioral effects that lead to depression [117]. One study has shown that a\nsingle dose of creatine can produce morphological alterations that contributed\nto the improvement of depressive-like behaviors triggered by chronic\ncorticosterone administration, like what was observed with the commonly used\nantidepressant medication, fluoxetine [118]. The effect of creatine on\ndepression in animal models appears to possibly be related to activation of\nthe rapid activation of the mammalian target of rapamycin complex 1 (mTORC1)\npathway, which can occur with a single dose of creatine [119]. Based on the\npre-clinical animal model literature, there is clear support for the possible\nuse of creatine in the treatment of depression.\n\nIn addition to the larger associative population study mentioned earlier\n[111], a number of case studies [120] and smaller-scale clinical trials have\nbeen published investigating the possible efficacy of creatine supplementation\nfor treating symptoms of depression [21,22,121,122,123,124]. In addition, a\nrecent extensive review focused on the use of creatine for the treatment of\ndepression [125]. Many of the studies have included mostly female participants\n[21,22,121,122,123,124,126]. Furthermore, most studies have looked at the\naugmentative effect of creatine to traditional pharmacological interventions\n[21,121]. Most studies have observed clinically relevant improvements and\nsuggest further investigation into the use of creatine as an intervention for\ndifferent forms of depression [21,22,120,121,122,123,124]. However, others\nhave not observed any benefit [126].\n\nCollectively, when looking at both the preclinical research and the limited\nnumber of small-scale human trials, the research suggests a possible role for\ncreatine supplementation in the treatment of different forms of depression.\nHowever, more larger-scale randomized control trials are warranted, and they\nshould include measurements of brain creatine and dietary measures to better\nunderstand habitual dietary intake of creatine on the response to such an\nintervention.\n\n### 5.2. Anxiety and Post-Traumatic Stress Disorder\n\nGeneralized anxiety disorder (GAD) is the second most common mental health\ndisorder in Canada, with a reported prevalence of 2.57% [103], while an\nestimated 70% of the population has experienced a traumatic event in their\nlifetime and 33% will experience three or more such events [127], which could\nlead to post-traumatic stress disorder (PTSD). There has been limited\ninvestigation into a possible role of creatine in GAD and PTSD. One study has\nsuggested that creatine levels are lower in white matter of patients with GAD\nthat was related to early trauma [128]. Similarly for PTSD, two studies have\ndescribed reduced creatine levels in the hippocampal region of the brain\n[129,130]. Despite these observations, there has been little investigation\ninto the possible use of creatine supplementation in these patient\npopulations.\n\nOne reported case study involving a 52-year-old woman who was diagnosed with\nPTSD, depression and fibromyalgia, observed improvements with 4 weeks of\ncreatine monohydrate supplementation [120]. The same group also reported\nimprovements with 4 weeks of creatine monohydrate supplementation in male and\nfemale patients diagnosed with PTSD who were receiving psychotropic treatment\n[131]. This group was deemed resistant to the psychotropic treatment, and with\nthe creatine monohydrate modest improvements in sleep and depression and PTSD\nsymptomology were observed [131]. Based on these limited observations, further\nwork is warranted in the possible use of creatine in the treatment of GAD and\nPTSD.\n\nGo to:\n\n## 6\\. Creatine for Concussion and Traumatic Brain Injury (TBI)\n\nAlthough the current body of research is limited, the utilization of creatine\nin the protection and management of concussion and mild traumatic brain injury\n(mTBI) has been noted as a particular area of interest\n[5,11,18,132,133,134,135,136]. The current treatment options to address\nphysiological dysfunction following concussion and mTBI is limited to aerobic\nexercise treatment; however, creatine is postulated to be another option which\ncould address aspects of the neurometabolic cascade associated with a\nconcussion or mTBI [137,138]. Specifically, immediately following a concussion\nor mTBI a state of hypermetabolism occurs which is then followed by a state of\nhypometabolism [138,139], however due to limited cerebral energy availability\nand injury-induced cerebral blood flow anomalies [140], energy supply and\ndemand are uncoupled [137]. Following mTBI, brain creatine content decreases\n[141,142] and, therefore, creatine supplementation could be beneficial in this\nscenario.\n\nCurrently, in vivo clinical research evaluating the efficacy of creatine\nsupplementation in humans is limited to a pilot study (n = 39) that reported\nbeneficial effects in children and adolescents (1\u201318 years of age) with a\nsevere TBI (Glasgow Coma Scale 3\u20139 on hospital admission) [143,144,145]. The\nauthors utilized an open label randomized design and found that creatine\nsupplementation (0.4 g/kg/day in an oral suspension administered by\nnasogastric tube or spoon) was associated with decreased duration of post-\ntraumatic amnesia, intubation and hospital stay, and elicited improvements in\nneurophysical, cognitive, personality/behavior and social aspects within 3\nmonths and, additionally, improved self-care at 6 months compared to control\n[143]. In follow-up publications from the same cohort of patients, it was\nreported that the creatine supplementation resulted in improvements in post-\ntraumatic headaches, dizziness and fatigue [144], as well as dysarthria and\nlingual problems of understanding [145]. Although clinical research is\nlimited, there are some pre-clinical studies evaluating the effectiveness of\ncreatine supplementation in TBI management.\n\nCreatine supplementation could play a protective role when consumed\nprophylactically. Sullivan et al. [146] found that mice injected with creatine\n(3 mg/g/day) for 3 or 5 days prior to a moderate controlled cortical contusion\nhad a 21% and 36% reduction in cortical damage, respectively, compared to\nplacebo at 7 days following injury. The authors also found that rats fed a\ncreatine-enriched diet (1% creatine) for 1 month following a TBI had a 50%\nreduction in cortical damage. It is suggested that these observed benefits\ncould be through the maintenance of mitochondrial membrane potential,\ndecreases in intramitochondrial reactive oxygen species and calcium, and\nmaintained ATP concentrations [146]. Supporting these findings, Scheff and\nDhillon [147] found that rats who received a diet enriched with 0.5% or 1%\ncreatine for 2 weeks prior to a moderate controlled cortical contusion had\ntissue sparing in the ipsilateral hemisphere compared to a placebo [147]. It\nwas postulated that the observed neuroprotection was due to the inhibition of\nlactic acid and free fatty acid accumulation found in the creatine\nsupplemented group [147]. Concussion and TBI are associated with the\nindiscriminate release of the excitatory amino acid glutamate which over\nactivates the N-methyl-D-asparate (NMDA) receptor resulting in increased\ncellular calcium (Ca^2+) which causes neuronal death, damage and dysfunction\n[148]. In a rodent hippocampal embryo cell culture model (>99% neuronal, <1%\nglial), the presence of creatine (5 mM) did not directly act as an\nantioxidant, however, creatine did mitigate excitotoxicity induced by a\nglutamate challenge, increased cellular ATP/PCr concentrations, reduced\noxidative stress induced glutamate overflow to the extracellular space, and\nreduced the Ca^2+ response to NMDA receptor stimulation [149]. Some evidence\nexists demonstrating that creatine could be beneficial when supplemented\nimmediately following TBI as well [150]. Saraiva et al. [150] found that\ncreatine supplementation in rats (300 mg/kg/day via intragastric gavage)\nprotected against oxidative stress damage as measured by protein carbonylation\nand thiobarbituric acid reactive species at 4 and 8 days post-TBI (induced by\nfluid percussion) but did not provide protection from seizures compared to\nplacebo [150].\n\nAlthough the current evidence is limited, the utilization of creatine\nsupplementation for the management and protection of concussion and TBI\nappears promising. The safety of creatine supplementation in humans is well\nestablished so future research examining its use in human clinical trials\nwould be of value. Further exploration of creatine supplementation, both prior\nto and following TBI, is required to determine an optimal consumption\nprotocol.\n\nGo to:\n\n## 7\\. Conclusions and Future Directions\n\nIt is well established that creatine supplementation can have favorable\neffects on measures of skeletal muscle mass and performance (i.e., strength).\nBeyond muscle, accumulating research shows that creatine supplementation and\nGAA can increase brain creatine content which may help explain some of the\npreliminary benefits from creatine supplementation on indices of cognition,\ndepression, concussion, and TBI. Research is lacking or inconsistent regarding\nthe efficacy of creatine for treating symptoms of neurodegenerative diseases,\nanxiety, or PTSD. Future research is needed to determine the mechanistic and\nclinical effects of longer-term creatine supplementation dosing strategies on\nbrain function and health. Future multifactorial interventions may also be\nrequired where creatine is combined with other strategies to enhance cognition\nor treat neurodegenerative diseases.\n\nGo to:\n\n## Author Contributions\n\nConceptualization: D.G.C. and S.C.F.; Writing\u2014Original Draft Preparation:\nS.C.F., D.M.C., S.M.C., B.G., H.R., S.M.O., E.S.R., B.D.R., K.P., P.G. and\nD.G.C. All authors have read and agreed to the published version of the\nmanuscript.\n\nGo to:\n\n## Funding\n\nThis research received no external funding.\n\nGo to:\n\n## Conflicts of Interest\n\nS.C.F. has previously served as a scientific advisor for a company that sold\ncreatine monohydrate and has received industry sponsored research involving\ncreatine supplementation and received creatine donations for scientific\nstudies. D.G.C. and E.S.R have conducted industry sponsored research involving\ncreatine supplementation and received creatine donations for scientific\nstudies and travel support for presentations involving creatine\nsupplementation at scientific conferences. In addition, D.G.C. and E.S.R serve\non the Scientific Advisory Board for Alzchem (a company that manufactures\ncreatine) and as an expert witness/consultant in legal cases involving\ncreatine supplementation. S.M.O. serves on the Scientific Advisory Board for\nAlzchem (a company that manufactures creatine). S.M.O. owns patent \u201cSports\nSupplements Based on Liquid Creatine\u201d at European Patent Office (WO2019150323\nA1), and active patent application \u201cSynergistic Creatine\u201d at UK Intellectual\nProperty Office (GB2012773.4). S.M.O. has served as a speaker at Abbott\nNutrition, a consultant of Allied Beverages Adriatic and IMLEK, and has\nreceived research funding related to creatine from the Serbian Ministry of\nEducation, Science, and Technological Development, Provincial Secretariat for\nHigher Education and Scientific Research, AlzChem GmbH, KW Pfannenschmidt\nGmbH, ThermoLife International LLC, and Hueston Hennigan LLP. S.M.O. does not\nown stocks and shares in any organization. D.M.C. is affiliated with the Pan\nAm Clinic Foundation which receives general education and research support\nfrom ConMed Linvatec, Ossur, Zimmer Biomet, and Arthrex. B.G. has received\nresearch grants, creatine donation for scientific studies, travel support for\nparticipation in scientific conferences (includes the ISSN) and honorarium for\nspeaking at lectures from AlzChem (a company which manufactures creatine). In\naddition, B.G. serves on the Scientific Advisory Board for Alzchem (a company\nthat manufactures creatine). All other authors report no conflicts of\ninterest.\n\nGo to:\n\n## Footnotes\n\nPublisher\u2019s Note: MDPI stays neutral with regard to jurisdictional claims in\npublished maps and institutional affiliations.\n\nGo to:\n\n## References\n\n1\\. Allen P.J. Creatine metabolism and psychiatric disorders: Does creatine\nsupplementation have therapeutic value? Neurosci. Biobehav. Rev. 2012;36:1462.\ndoi: 10.1016/j.neubiorev.2012.03.005. [PMC free article] [PubMed] [CrossRef]\n[Google Scholar]\n\n2\\. Snow W., Cadonic C., Cortes-Perez C., Roy Chowdhury S., Djordjevic J.,\nThomson E., Bernstein M., Suh M., Fernyhough P., Albensi B. Chronic dietary\ncreatine enhances hippocampal-dependent spatial memory, bioenergetics, and\nlevels of plasticity-related proteins associated with NF-\u03baB. Learn. Mem.\n2018;25:54\u201366. doi: 10.1101/lm.046284.117. [PMC free article] [PubMed]\n[CrossRef] [Google Scholar]\n\n3\\. Forbes S., Candow D., Ferreira L., Souza-Junior T. Effects of creatine\nsupplementation on properties of muscle, bone, and brain function in older\nadults: A narrative review. J. Diet. Suppl. 2021:1\u201318. doi:\n10.1080/19390211.2021.1877232. [PubMed] [CrossRef] [Google Scholar]\n\n4\\. Ricci T., Forbes S.C., Candow D.G. Creatine supplementation: Practical\nstrategies and considerations for mixed martial arts. J. Exerc. Nutr.\n2020;3:s2. [Google Scholar]\n\n5\\. Roschel H., Gualano B., Ostojic S.M., Rawson E.S. Creatine Supplementation\nand Brain Health. Nutrients. 2021;13:586. doi: 10.3390/nu13020586. [PMC free\narticle] [PubMed] [CrossRef] [Google Scholar]\n\n6\\. Wyss M., Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol.\nRev. 2000;80:1107\u20131213. doi: 10.1152/physrev.2000.80.3.1107. [PubMed]\n[CrossRef] [Google Scholar]\n\n7\\. Wallimann T., Dolder M., Schlattner U., Eder M., Hornemann T., Kraft T.,\nStolz M. Creatine kinase: An enzyme with a central role in cellular energy\nmetabolism. MAGMA. 1998;6:116\u2013119. doi: 10.1007/BF02660927. [PubMed]\n[CrossRef] [Google Scholar]\n\n8\\. Fernandes-Pires G., Braissant O. Current and potential new treatment\nstrategies for creatine deficiency syndromes. Mol. Genet. Metab.\n2022;135:15\u201326. doi: 10.1016/j.ymgme.2021.12.005. [PubMed] [CrossRef] [Google\nScholar]\n\n9\\. Harris R., S\u00f6derlund K., Hultman E. Elevation of creatine in resting and\nexercised muscle of normal subjects by creatine supplementation. Clin. Sci.\n1992;83:367\u2013374. doi: 10.1042/cs0830367. [PubMed] [CrossRef] [Google Scholar]\n\n10\\. Hultman E., Soderlund K., Timmons J.A., Cederblad G., Greenhaff P.L.\nMuscle Creatine Loading in Men. J. Appl. Physiol. 1996;81:232\u2013237. doi:\n10.1152/jappl.1996.81.1.232. [PubMed] [CrossRef] [Google Scholar]\n\n11\\. Kreider R., Kalman D., Antonio J., Ziegenfuss T., Wildman R., Collins R.,\nCandow D., Kleiner S., Almada A., Lopez H. International Society of Sports\nNutrition position stand: Safety and efficacy of creatine supplementation in\nexercise, sport, and medicine. J. Int. Soc. Sports Nutr. 2017;14:18. doi:\n10.1186/s12970-017-0173-z. [PMC free article] [PubMed] [CrossRef] [Google\nScholar]\n\n12\\. Robinson T.M., Sewell D.A., Hultman E., Greenhaff P.L. Role of submaximal\nexercise in promoting creatine and glycogen accumulation in human skeletal\nmuscle. J. Appl. Physiol. 1999;87:598\u2013604. doi: 10.1152/jappl.1999.87.2.598.\n[PubMed] [CrossRef] [Google Scholar]\n\n13\\. Steenge G.R., Lambourne J., Casey A., Macdonald I.A., Greenhaff P.L.\nStimulatory effect of insulin on creatine accumulation in human skeletal\nmuscle. Am. J. Physiol. Endocrinol. Metab. 1998;275:E974\u2013E979. doi:\n10.1152/ajpendo.1998.275.6.E974. [PubMed] [CrossRef] [Google Scholar]\n\n14\\. Green A., Hultman E., Macdonald I., Sewell D., Greenhaff P. Carbohydrate\ningestion augments skeletal muscle creatine accumulation during creatine\nsupplementation in humans. Am. J. Physiol. 1996;271:E821\u2013E826. doi:\n10.1152/ajpendo.1996.271.5.E821. [PubMed] [CrossRef] [Google Scholar]\n\n15\\. Steenge G.R., Simpson E.J., Greenhaff P.L. Protein- and carbohydrate-\ninduced augmentation of whole body creatine retention in humans. J. Appl.\nPhysiol. 2000;89:1165\u20131171. doi: 10.1152/jappl.2000.89.3.1165. [PubMed]\n[CrossRef] [Google Scholar]\n\n16\\. Burke D.G., Chilibeck P.D., Parise G., Tarnopolsky M.A., Candow D.G.\nEffect of alpha-lipoic acid combined with creatine monohydrate on human\nskeletal muscle creatine and phosphagen concentration. Int. J. Sport Nutr.\nExerc. Metab. 2003;13:294\u2013302. doi: 10.1123/ijsnem.13.3.294. [PubMed]\n[CrossRef] [Google Scholar]\n\n17\\. Avgerinos K.I., Spyrou N., Bougioukas K.I., Kapogiannis D. Effects of\ncreatine supplementation on cognitive function of healthy individuals: A\nsystematic review of randomized controlled trials. Exp. Gerontol.\n2018;108:173. doi: 10.1016/j.exger.2018.04.013. [PMC free article] [PubMed]\n[CrossRef] [Google Scholar]\n\n18\\. Dolan E., Gualano B., Rawson E.S. Beyond muscle: The effects of creatine\nsupplementation on brain creatine, cognitive processing, and traumatic brain\ninjury. Eur. J. Sport Sci. 2019;19:1\u201314. doi: 10.1080/17461391.2018.1500644.\n[PubMed] [CrossRef] [Google Scholar]\n\n19\\. Dechent P., Pouwels P.J.W., Wilken B., Hanefeld F., Frahm J. Increase of\ntotal creatine in human brain after oral supplementation of creatine-\nmonohydrate. Am. J. Physiol. Regul. Integr. Comp. Physiol. 1999;46:R698\u2013R704.\ndoi: 10.1152/ajpregu.1999.277.3.R698. [PubMed] [CrossRef] [Google Scholar]\n\n20\\. Pan J.W., Takahashi K. Cerebral energetic effects of creatine\nsupplementation in humans. Am. J. Physiol. Regul. Integr. Comp. Physiol.\n2007;292:R1745. doi: 10.1152/ajpregu.00717.2006. [PMC free article] [PubMed]\n[CrossRef] [Google Scholar]\n\n21\\. Kondo D.G., Sung Y.H., Hellem T.L., Fiedler K.K., Shi X., Jeong E.K.,\nRenshaw P.F. Open-label adjunctive creatine for female adolescents with SSRI-\nresistant major depressive disorder: A 31-phosphorus magnetic resonance\nspectroscopy study. J. Affect. Disord. 2011;135:354\u2013361. doi:\n10.1016/j.jad.2011.07.010. [PMC free article] [PubMed] [CrossRef] [Google\nScholar]\n\n22\\. Hellem T.L., Sung Y.-H., Shi X.-F., Pett M.A., Latendresse G., Morgan J.,\nHuber R.S., Kuykendall D., Lundberg K.J., Renshaw P.F. Creatine as a Novel\nTreatment for Depression in Females Using Methamphetamine: A Pilot Study. J.\nDual Diagn. 2015;11:189\u2013202. doi: 10.1080/15504263.2015.1100471. [PMC free\narticle] [PubMed] [CrossRef] [Google Scholar]\n\n23\\. Turner C.E., Byblow W.D., Gant N. Creatine Supplementation Enhances\nCorticomotor Excitability and Cognitive Performance during Oxygen Deprivation.\nJ. Neurosci. 2015;35:1773. doi: 10.1523/JNEUROSCI.3113-14.2015. [PMC free\narticle] [PubMed] [CrossRef] [Google Scholar]\n\n24\\. Solis M., Artioli G., Otaduy M., Leite C., Arruda W., Veiga R., Gualano\nB. Effect of age, diet, and tissue type on PCr response to creatine\nsupplementation. J. Appl. Physiol. 2017;123:407\u2013414. doi:\n10.1152/japplphysiol.00248.2017. [PubMed] [CrossRef] [Google Scholar]\n\n25\\. Lyoo I.K., Kong S.W., Sung S.M., Hirashima F., Parow A., Hennen J., Cohen\nB.M., Renshaw P.F. Multinuclear magnetic resonance spectroscopy of high-energy\nphosphate metabolites in human brain following oral supplementation of\ncreatine-monohydrate. Psychiatry Res. 2003;123:87\u2013100. doi:\n10.1016/S0925-4927(03)00046-5. [PubMed] [CrossRef] [Google Scholar]\n\n26\\. Turner C.E., Russell B.R., Gant N. Comparative quantification of dietary\nsupplemented neural creatine concentrations with (1)H-MRS peak fitting and\nbasis spectrum methods. Magn. Reson. Imaging. 2015;33:1163\u20131167. doi:\n10.1016/j.mri.2015.06.018. [PubMed] [CrossRef] [Google Scholar]\n\n27\\. Wilkinson I.D., Mitchel N., Breivik S., Greenwood P., Griffiths P.D.,\nWinter E.M., Van Beek E.J.R. Effects of creatine supplementation on cerebral\nwhite matter in competitive sportsmen. Clin. J. Sport Med. 2006;16:63\u201367. doi:\n10.1097/01.jsm.0000176372.67398.c8. [PubMed] [CrossRef] [Google Scholar]\n\n28\\. Merege-Filho C.A.A., Otaduy M.C.G., de S\u00e1-Pinto A.L., de Oliveira M.O.,\nde Souza Gon\u00e7alves L., Hayashi A.P.T., Roschel H., Pereira R.M.R., Silva C.A.,\nBrucki S.M.D., et al. Does brain creatine content rely on exogenous creatine\nin healthy youth? A proof-of-principle study. Appl. Physiol. Nutr. Metab.\n2016;42:128\u2013134. doi: 10.1139/apnm-2016-0406. [PubMed] [CrossRef] [Google\nScholar]\n\n29\\. Braissant O., Bachmann C., Henry H. Expression and function of AGAT, GAMT\nand CT1 in the mammalian brain. Subcell. Biochem. 2007;46:67\u201381. doi:\n10.1007/978-1-4020-6486-9_4. [PubMed] [CrossRef] [Google Scholar]\n\n30\\. Andres R.H., Ducray A.D., Schlattner U., Wallimann T., Widmer H.R.\nFunctions and effects of creatine in the central nervous system. Brain Res.\nBull. 2008;76:329\u2013343. doi: 10.1016/j.brainresbull.2008.02.035. [PubMed]\n[CrossRef] [Google Scholar]\n\n31\\. B\u00e9ard E., Braissant O. Synthesis and transport of creatine in the CNS:\nImportance for cerebral functions. J. Neurochem. 2010;115:297\u2013313. doi:\n10.1111/j.1471-4159.2010.06935.x. [PubMed] [CrossRef] [Google Scholar]\n\n32\\. Salomons G.S., Van Dooren S.J.M., Verhoeven N.M., Marsden D., Schwartz\nC., Cecil K.M., DeGrauw T.J., Jakobs C. X-linked creatine transporter defect:\nAn overview. J. Inherit. Metab. Dis. 2003;26:309\u2013318. doi:\n10.1023/A:1024405821638. [PubMed] [CrossRef] [Google Scholar]\n\n33\\. Jagim A.R., Kerksick C.M. Creatine Supplementation in Children and\nAdolescents. Nutrients. 2021;13:664. doi: 10.3390/nu13020664. [PMC free\narticle] [PubMed] [CrossRef] [Google Scholar]\n\n34\\. St\u00f6ckler S., Holzbach U., Hanefeld F., Marquardt I., Helms G., Requar\nT.M., Hanicke W., Frahm J. Creatine deficiency in the brain: A new, treatable\ninborn error of metabolism. Pediatr. Res. 1994;36:409\u2013413. doi:\n10.1203/00006450-199409000-00023. [PubMed] [CrossRef] [Google Scholar]\n\n35\\. Borsook M., Billig H., Golseth J. Betaine and glycocyamine in the\ntreatment of disability resulting from acute anterior poliomyelitis. Ann.\nWest. Med. Surg. 1952;6:423\u2013427. [PubMed] [Google Scholar]\n\n36\\. Fallis B.D., Lam R.L. Betaine and glycocyamine therapy for the chronic\nresiduals of poliomyelitis. J. Am. Med. Assoc. 1952;150:851\u2013853. doi:\n10.1001/jama.1952.03680090015007. [PubMed] [CrossRef] [Google Scholar]\n\n37\\. Aldes J. Glycocyamine betaine as an adjunct in the treatment of\nneuromuscular disease patients. J. Ark. Med. Soc. 1957;54:186\u2013194. [PubMed]\n[Google Scholar]\n\n38\\. Watkins A.L. Betaine and glycocyamine in the treatment of poliomyelitis.\nN. Engl. J. Med. 1953;248:621\u2013623. doi: 10.1056/NEJM195304092481501. [PubMed]\n[CrossRef] [Google Scholar]\n\n39\\. Liveksedge L.A. Glycocyamine and betaine in motor-neurone disease.\nLancet. 1956;271:1136\u20131138. doi: 10.1016/S0140-6736(56)90154-4. [PubMed]\n[CrossRef] [Google Scholar]\n\n40\\. McBreairty L.E., Robinson J.L., Furlong K.R., Brunton J.A., Bertolo R.F.\nGuanidinoacetate is more effective than creatine at enhancing tissue creatine\nstores while consequently limiting methionine availability in Yucatan\nminiature pigs. PLoS ONE. 2015;10:e0131563. doi: 10.1371/journal.pone.0131563.\n[PMC free article] [PubMed] [CrossRef] [Google Scholar]\n\n41\\. Ostojic S.M., Ostojic J., Drid P., Vranes M. Guanidinoacetic acid versus\ncreatine for improved brain and muscle creatine levels: A superiority pilot\ntrial in healthy men. Appl. Physiol. Nutr. Metab. 2016;41:1005\u20131007. doi:\n10.1139/apnm-2016-0178. [PubMed] [CrossRef] [Google Scholar]\n\n42\\. Ostojic S.M., Ostojic J., Drid P., Vranes M., Jovanov P. Dietary\nguanidinoacetic acid increases brain creatine levels in healthy men.\nNutrition. 2017;33:149\u2013156. doi: 10.1016/j.nut.2016.06.001. [PubMed]\n[CrossRef] [Google Scholar]\n\n43\\. Semeredi S., Stajer V., Ostojic J., Vranes M., Ostojic S.M.\nGuanidinoacetic acid with creatine compared with creatine alone for tissue\ncreatine content, hyperhomocysteinemia, and exercise performance: A\nrandomized, double-blind superiority trial. Nutrition. 2019;57:162\u2013166. doi:\n10.1016/j.nut.2018.04.009. [PubMed] [CrossRef] [Google Scholar]\n\n44\\. Ostojic S.M. Guanidinoacetic acid loading for improved location-specific\nbrain creatine. Clin. Nutr. 2021;40:324\u2013326. doi: 10.1016/j.clnu.2020.05.003.\n[PubMed] [CrossRef] [Google Scholar]\n\n45\\. Robinson J.L., McBreairty L.E., Ryan R.A., Randunu R., Walsh C.J., Martin\nG.M., Brunton J.A., Bertolo R.F. Effects of supplemental creatine and\nguanidinoacetic acid on spatial memory and the brain of weaned Yucatan\nminiature pigs. PLoS ONE. 2020;15:e0226806. doi: 10.1371/journal.pone.0226806.\n[PMC free article] [PubMed] [CrossRef] [Google Scholar]\n\n46\\. Ostojic S.M., Stojanovic M., Drid P., Hoffman J.R., Sekulic D., Zenic N.\nSupplementation with Guanidinoacetic Acid in Women with Chronic Fatigue\nSyndrome. Nutrients. 2016;8:72. doi: 10.3390/nu8020072. [PMC free article]\n[PubMed] [CrossRef] [Google Scholar]\n\n47\\. Seper V., Korovljev D., Todorovic N., Stajer V., Ostojic J., Nesic N.,\nOstojic S.M. Guanidinoacetate-Creatine Supplementation Improves Functional\nPerformance and Muscle and Brain Bioenergetics in the Elderly: A Pilot Study.\nAnn. Nutr. Metab. 2021;77:244\u2013247. doi: 10.1159/000518499. [PubMed] [CrossRef]\n[Google Scholar]\n\n48\\. Ostojic S.M. Tackling guanidinoacetic acid for advanced cellular\nbioenergetics. Nutrition. 2017;34:55\u201357. doi: 10.1016/j.nut.2016.09.010.\n[PubMed] [CrossRef] [Google Scholar]\n\n49\\. Takahashi H., Arai B., Koshino C. Effects of guanidinoacetic acid, gamma-\nguanidinobutyric acid and gamma-guanidinobutyryl-methylester on the mammalian\ncerebral cortex. Jpn. J. Physiol. 1961;11:403\u2013409. doi:\n10.2170/jjphysiol.11.403. [PubMed] [CrossRef] [Google Scholar]\n\n50\\. Neu A., Neuhoff H., Trube G., Fehr S., Ullrich K., Roeper J., Isbrandt D.\nActivation of GABA(A) receptors by guanidinoacetate: A novel\npathophysiological mechanism. Neurobiol. Dis. 2002;11:298\u2013307. doi:\n10.1006/nbdi.2002.0547. [PubMed] [CrossRef] [Google Scholar]\n\n51\\. Zugno A.I., Stefanello F.M., Streck E.L., Calcagnotto T., Wannmacher\nC.M.D., Wajner M., Wyse A.T.S. Inhibition of Na^+, K^+-ATPase activity in rat\nstriatum by guanidinoacetate. Int. J. Dev. Neurosci. 2003;21:183\u2013189. doi:\n10.1016/S0736-5748(03)00038-8. [PubMed] [CrossRef] [Google Scholar]\n\n52\\. Zugno A.I., Scherer E.B.S., Schuck P.F., Oliveira D.L., Wofchuk S.,\nWannmacher C.M.D., Wajner M., Wyse A.T.S. Intrastriatal administration of\nguanidinoacetate inhibits Na^+, K^+-ATPase and creatine kinase activities in\nrat striatum. Metab. Brain Dis. 2006;21:41\u201350. doi: 10.1007/s11011-006-9003-8.\n[PubMed] [CrossRef] [Google Scholar]\n\n53\\. Zugno A.I., Scherer E.B.S., Mattos C., Ribeiro C.A.J., Wannmacher C.M.D.,\nWajner M., Wyse A.T.S. Evidence that the inhibitory effects of\nguanidinoacetate on the activities of the respiratory chain, Na^+, K^+-ATPase\nand creatine kinase can be differentially prevented by taurine and vitamins E\nand C administration in rat striatum in vivo. Biochim. Biophys. Acta.\n2007;1772:563\u2013569. doi: 10.1016/j.bbadis.2007.02.005. [PubMed] [CrossRef]\n[Google Scholar]\n\n54\\. Zugno A.I., Oliveira D.L., Scherer E.B.S., Wajner M., Wofchuk S., Wyse\nA.T.S. Guanidinoacetate inhibits glutamate uptake in rat striatum of rats at\ndifferent ages. Neurochem. Res. 2007;32:959\u2013964. doi:\n10.1007/s11064-006-9245-1. [PubMed] [CrossRef] [Google Scholar]\n\n55\\. Zugno A.I., Pereira L.O., Mattos C., Scherer E.B.S., Netto C.A., Wyse\nA.T.S. Guanidinoacetate administration increases acetylcholinesterase activity\nin striatum of rats and impairs retention of an inhibitory avoidance task.\nMetab. Brain Dis. 2008;23:189\u2013198. doi: 10.1007/s11011-008-9085-6. [PubMed]\n[CrossRef] [Google Scholar]\n\n56\\. Zugno A.I., Stefanello F.M., Scherer E.B.S., Mattos C., Pederzolli C.D.,\nAndrade V.M., Wannmacher C.M.D., Wajner M., Dutra-Filho C.S., Wyse A.T.S.\nGuanidinoacetate decreases antioxidant defenses and total protein sulfhydryl\ncontent in striatum of rats. Neurochem. Res. 2008;33:1804\u20131810. doi:\n10.1007/s11064-008-9636-6. [PubMed] [CrossRef] [Google Scholar]\n\n57\\. Ostojic S.M., Ostojic J. Dietary guanidinoacetic acid does not accumulate\nin the brain of healthy men. Eur. J. Nutr. 2018;57:3003\u20133005. doi:\n10.1007/s00394-017-1600-2. [PubMed] [CrossRef] [Google Scholar]\n\n58\\. Gillessen T., Budd S.L., Lipton S.A. Excitatory amino acid neurotoxicity.\nAdv. Exp. Med. Biol. 2002;513:3\u201340. doi: 10.1007/978-1-4615-0123-7_1. [PubMed]\n[CrossRef] [Google Scholar]\n\n59\\. Bender A., Klopstock T. Creatine for neuroprotection in neurodegenerative\ndisease: End of story? Amin. Acids. 2016;48:1929\u20131940. doi:\n10.1007/s00726-015-2165-0. [PubMed] [CrossRef] [Google Scholar]\n\n60\\. Mercimek-Andrews S., Salomons G.S. Creatine Deficiency Syndromes. Inborn\nMetab. Dis. Diagn. Treat. 2015:239\u2013247. [Google Scholar]\n\n61\\. Kaldis P., Hemmer W., Zanolla E., Holtzman D., Wallimann T. \u201cHot spots\u201d\nof creatine kinase localization in brain: Cerebellum, hippocampus and choroid\nplexus. Dev. Neurosci. 1996;18:542\u2013554. doi: 10.1159/000111452. [PubMed]\n[CrossRef] [Google Scholar]\n\n62\\. Borchio L., MacHek S.B., MacHado M. Supplemental creatine monohydrate\nloading improves cognitive function in experienced mountain bikers. J. Sports\nMed. Phys. Fit. 2020;60:1168\u20131170. doi: 10.23736/S0022-4707.20.10589-9.\n[PubMed] [CrossRef] [Google Scholar]\n\n63\\. Benton D., Donohoe R. The influence of creatine supplementation on the\ncognitive functioning of vegetarians and omnivores. Br. J. Nutr.\n2011;105:1100\u20131105. doi: 10.1017/S0007114510004733. [PubMed] [CrossRef]\n[Google Scholar]\n\n64\\. McMorris T., Mielcarz G., Harris R., Swain J., Howard A. Creatine\nsupplementation and cognitive performance in elderly individuals.\nNeuropsychol. Dev. Cogn. B. Aging. Neuropsychol. Cogn. 2007;14:517\u2013528. doi:\n10.1080/13825580600788100. [PubMed] [CrossRef] [Google Scholar]\n\n65\\. Hammett S.T., Wall M.B., Edwards T.C., Smith A.T. Dietary supplementation\nof creatine monohydrate reduces the human fMRI BOLD signal. Neurosci. Lett.\n2010;479:201\u2013205. doi: 10.1016/j.neulet.2010.05.054. [PubMed] [CrossRef]\n[Google Scholar]\n\n66\\. Ling J., Kritikos M., Tiplady B. Cognitive effects of creatine ethyl\nester supplementation. Behav. Pharmacol. 2009;20:673\u2013679. doi:\n10.1097/FBP.0b013e3283323c2a. [PubMed] [CrossRef] [Google Scholar]\n\n67\\. McMorris T., Harris R.C., Howard A.N., Langridge G., Hall B., Corbett J.,\nDicks M., Hodgson C. Creatine supplementation, sleep deprivation, cortisol,\nmelatonin and behavior. Physiol. Behav. 2007;90:21\u201328. doi:\n10.1016/j.physbeh.2006.08.024. [PubMed] [CrossRef] [Google Scholar]\n\n68\\. McMorris T., Harris R.C., Swain J., Corbett J., Collard K., Dyson R.J.,\nDye L., Hodgson C., Draper N. Effect of creatine supplementation and sleep\ndeprivation, with mild exercise, on cognitive and psychomotor performance,\nmood state, and plasma concentrations of catecholamines and cortisol.\nPsychopharmacology. 2006;185:93\u2013103. doi: 10.1007/s00213-005-0269-z. [PubMed]\n[CrossRef] [Google Scholar]\n\n69\\. Smolarek A.C., Mcanulty S.R., Ferreira L.H., Cordeiro G.R., Alessi A.,\nRebesco D.B., Honorato I.C., Laat E.F., Mascarenhas L.P., Souza-Junior T.P.,\net al. Effect of 16 Weeks of Strength Training and Creatine Supplementation on\nStrength and Cognition in Older Adults: A Pilot Study. J. Exerc. Physiol.\n2020;23:88\u201394. [Google Scholar]\n\n70\\. VAN Cutsem J., Roelands B., Pluym B., Tassignon B., Verschueren J., DE\nPauw K., Meeusen R. Can Creatine Combat the Mental Fatigue-associated Decrease\nin Visuomotor Skills? Med. Sci. Sports Exerc. 2020;52:120\u2013130. doi:\n10.1249/MSS.0000000000002122. [PubMed] [CrossRef] [Google Scholar]\n\n71\\. Watanabe A., Kato N., Kato T. Effects of creatine on mental fatigue and\ncerebral hemoglobin oxygenation. Neurosci. Res. 2002;42:279\u2013285. doi:\n10.1016/S0168-0102(02)00007-X. [PubMed] [CrossRef] [Google Scholar]\n\n72\\. Pires L.A.M., Forbes S.C., Candow D.G., Machado M. Creatine\nsupplementation on cognitive performance following Creatine supplementation on\ncognitive performance following exercise in female Muay Thai athletes exercise\nin female Muay Thai athletes. J. Soc. NeuroSports. 2020;1:6. [Google Scholar]\n\n73\\. Rawson E.S., Lieberman H.R., Walsh T.M., Zuber S.M., Harhart J.M.,\nMatthews T.C. Creatine supplementation does not improve cognitive function in\nyoung adults. Physiol. Behav. 2008;95:130\u2013134. doi:\n10.1016/j.physbeh.2008.05.009. [PubMed] [CrossRef] [Google Scholar]\n\n74\\. Alves C.R.R., Filho C.A.A.M., Benatti F.B., Brucki S., Pereira R.M.R., de\nS\u00e3o Pinto A.L., Lima F.R., Roschel H., Gualano B. Creatine supplementation\nassociated or not with strength training upon emotional and cognitive measures\nin older women: A randomized double-blind study. PLoS ONE. 2013;8:e76301. doi:\n10.1371/journal.pone.0076301. [PMC free article] [PubMed] [CrossRef] [Google\nScholar]\n\n75\\. Rae C., Digney A.L., McEwan S.R., Bates T.C. Oral creatine monohydrate\nsupplementation improves brain performance: A double-blind, placebo-\ncontrolled, cross-over trial. Proc. R. Soc. B Biol. Sci. 2003;270:2147. doi:\n10.1098/rspb.2003.2492. [PMC free article] [PubMed] [CrossRef] [Google\nScholar]\n\n76\\. Harmon K.K., Stout J.R., Fukuda D.H., Pabian P.S., Rawson E.S., Stock\nM.S. The Application of Creatine Supplementation in Medical Rehabilitation.\nNutrients. 2021;13:1825. doi: 10.3390/nu13061825. [PMC free article] [PubMed]\n[CrossRef] [Google Scholar]\n\n77\\. Gualano B., Artioli G.G., Poortmans J.R., Lancha Junior A.H. Exploring\nthe therapeutic role of creatine supplementation. Amino Acids. 2010;38:31\u201344.\ndoi: 10.1007/s00726-009-0263-6. [PubMed] [CrossRef] [Google Scholar]\n\n78\\. Klopstock T., Elstner M., Bender A. Creatine in mouse models of\nneurodegeneration and aging. Amino Acids. 2011;40:1297\u20131303. doi:\n10.1007/s00726-011-0850-1. [PubMed] [CrossRef] [Google Scholar]\n\n79\\. Xu C.J., Klunk W.E., Kanfe J.N., Xiong Q., Miller G., Pettegrew J.W.\nPhosphocreatine-dependent glutamate uptake by synaptic vesicles. A comparison\nwith atp-dependent glutamate uptake. J. Biol. Chem. 1996;271:13435\u201313440. doi:\n10.1074/jbc.271.23.13435. [PubMed] [CrossRef] [Google Scholar]\n\n80\\. Beal M.F. Neuroprotective effects of creatine. Amino Acids.\n2011;40:1305\u20131313. doi: 10.1007/s00726-011-0851-0. [PubMed] [CrossRef] [Google\nScholar]\n\n81\\. Mazzini L., Balzarini C., Colombo R., Mora G., Pastore I., De Ambrogio\nR., Caligari M. Effects of creatine supplementation on exercise performance\nand muscular strength in amyotrophic lateral sclerosis: Preliminary results.\nJ. Neurol. Sci. 2001;191:139\u2013144. doi: 10.1016/S0022-510X(01)00611-6. [PubMed]\n[CrossRef] [Google Scholar]\n\n82\\. Groeneveld G.J., Veldink J.H., Van der Tweel I., Kalmijn S., Beijer C.,\nDe Visser M., Wokke J.H.J., Franssen H., Van den Berg L.H. A randomized\nsequential trial of creatine in amyotrophic lateral sclerosis. Ann. Neurol.\n2003;53:437\u2013445. doi: 10.1002/ana.10554. [PubMed] [CrossRef] [Google Scholar]\n\n83\\. Rosenfeld J., King R.M., Jackson C.E., Bedlack R.S., Barohn R.J., Dick\nA., Phillips L.H., Chapin J., Gelinas D.F., Lou J.S. Creatine monohydrate in\nALS: Effects on strength, fatigue, respiratory status and ALSFRS. Amyotroph.\nLateral Scler. 2008;9:266\u2013272. doi: 10.1080/17482960802028890. [PMC free\narticle] [PubMed] [CrossRef] [Google Scholar]\n\n84\\. Shefner J.M., Cudkowicz M.E., Schoenfeld D., Conrad T., Taft J., Chilton\nM., Urbinelli L., Qureshi M., Zhang H., Pestronk A., et al. A clinical trial\nof creatine in ALS. Neurology. 2004;63:1656\u20131661. doi:\n10.1212/01.WNL.0000142992.81995.F0. [PubMed] [CrossRef] [Google Scholar]\n\n85\\. Passamano L., Taglia A., Palladino A., Viggiano E., D\u2019Ambrosio P.,\nScutifero M., Cecio M.R., Torre V., De Luca F., Picillo E., et al. Improvement\nof survival in DuchenneMuscular Dystrophy: Retrospective analysisof 835\npatients. Acta Myol. 2012;31:125. [PMC free article] [PubMed] [Google Scholar]\n\n86\\. Louis M., Lebacq J., Poortmans J.R., Belpaire-Dethiou M.-C., Devogelaer\nJ.-P., Van Hecke P., Goubel F., Francaux M. Beneficial effects of creatine\nsupplementation in dystrophic patients. Muscle Nerve. 2003;27:604\u2013610. doi:\n10.1002/mus.10355. [PubMed] [CrossRef] [Google Scholar]\n\n87\\. Tarnopolsky M.A., Mahoney D.J., Vajsar J., Rodriguez C., Doherty T.J.,\nRoy B.D., Biggar D. Creatine monohydrate enhances strength and body\ncomposition in Duchenne muscular dystrophy. Neurology. 2004;62:1771\u20131777. doi:\n10.1212/01.WNL.0000125178.18862.9D. [PubMed] [CrossRef] [Google Scholar]\n\n88\\. Escolar D., Buyse G., Henricson E., Leshner R., Florence J., Mayhew J.,\nTesi-Rocha C., Gorni K., Pasquali L., Patel K., et al. CINRG randomized\ncontrolled trial of creatine and glutamine in Duchenne muscular dystrophy.\nAnn. Neurol. 2005;58:151\u2013155. doi: 10.1002/ana.20523. [PubMed] [CrossRef]\n[Google Scholar]\n\n89\\. Hersch S.M., Gevorkian S., Marder K., Moskowitz C., Feigin A., Cox M.,\nComo P., Zimmerman C., Lin M., Zhang L., et al. Creatine in Huntington disease\nis safe, tolerable, bioavailable in brain and reduces serum 8OH2\u2019dG.\nNeurology. 2006;66:250\u2013252. doi: 10.1212/01.wnl.0000194318.74946.b6. [PubMed]\n[CrossRef] [Google Scholar]\n\n90\\. Tabrizi S.J., Blamire A.M., Manners D.N., Rajagopalan B., Styles P.,\nSchapira A.H.V., Warner T.T. High-dose creatine therapy for Huntington\ndisease: A 2-year clinical and MRS study. Neurology. 2005;64:1655\u20131656. doi:\n10.1212/01.WNL.0000160388.96242.77. [PubMed] [CrossRef] [Google Scholar]\n\n91\\. Tabrizi S.J., Blamire A.M., Manners D.N., Rajagopalan B., Styles P.,\nSchapira A.H.V., Warner T.T. Creatine therapy for Huntington\u2019s disease:\nClinical and MRS findings in a 1-year pilot study. Neurology. 2003;61:141\u2013142.\ndoi: 10.1212/01.WNL.0000070186.97463.A7. [PubMed] [CrossRef] [Google Scholar]\n\n92\\. Verbessem P., Lemiere J., Eijnde B.O., Swinnen S., Vanhees L., Van\nLeemputte M., Hespel P., Dom R. Creatine supplementation in Huntington\u2019s\ndisease: A placebo-controlled pilot trial. Neurology. 2003;61:925\u2013930. doi:\n10.1212/01.WNL.0000090629.40891.4B. [PubMed] [CrossRef] [Google Scholar]\n\n93\\. Bender A., Auer D.P., Merl T., Reilmann R., Saemann P., Yassouridis A.,\nBender J., Weindl A., Dose M., Gasser T., et al. Creatine supplementation\nlowers brain glutamate levels in Huntington\u2019s disease. J. Neurol.\n2005;252:36\u201341. doi: 10.1007/s00415-005-0595-4. [PubMed] [CrossRef] [Google\nScholar]\n\n94\\. Hersch S.M., Schifitto G., Oakes D., Bredlau A.L., Meyers C.M., Nahin R.,\nRosas H.D. The CREST-E study of creatine for Huntington disease: A randomized\ncontrolled trial. Neurology. 2017;89:594\u2013601. doi:\n10.1212/WNL.0000000000004209. [PMC free article] [PubMed] [CrossRef] [Google\nScholar]\n\n95\\. Lambert C.P., Archer R.L., Carrithers J.A., Fink W.J., Evans W.J., Trappe\nT.A. Influence of creatine monohydrate ingestion on muscle metabolites and\nintense exercise capacity in individuals with multiple sclerosis. Arch. Phys.\nMed. Rehabil. 2003;84:1206\u20131210. doi: 10.1016/S0003-9993(03)00262-4. [PubMed]\n[CrossRef] [Google Scholar]\n\n96\\. Malin S.K., Cotugna N., Fang C.S. Effect of creatine supplementation on\nmuscle capacity in individuals with multiple sclerosis. J. Diet. Suppl.\n2008;5:20\u201332. doi: 10.1080/19390210802328974. [PubMed] [CrossRef] [Google\nScholar]\n\n97\\. Olanow C.W., Stern M.B., Sethi K. The scientific and clinical basis for\nthe treatment of Parkinson disease (2009) Neurology. 2009;72:S1\u2013S136. doi:\n10.1212/WNL.0b013e3181a1d44c. [PubMed] [CrossRef] [Google Scholar]\n\n98\\. Yang L., Calingasan N.Y., Wille E.J., Cormier K., Smith K., Ferrante\nR.J., Flint Beal M. Combination therapy with coenzyme Q10 and creatine\nproduces additive neuroprotective effects in models of Parkinson\u2019s and\nHuntington\u2019s diseases. J. Neurochem. 2009;109:1427\u20131439. doi:\n10.1111/j.1471-4159.2009.06074.x. [PMC free article] [PubMed] [CrossRef]\n[Google Scholar]\n\n99\\. Bender A., Koch W., Elstner M., Schombacher Y., Bender J., Moeschl M.,\nGekeler F., M\u00fcller-Myhsok B., Gasser T., Tatsch K., et al. Creatine\nsupplementation in Parkinson disease: A placebo-controlled randomized pilot\ntrial. Neurology. 2006;67:1262\u20131264. doi: 10.1212/01.wnl.0000238518.34389.12.\n[PubMed] [CrossRef] [Google Scholar]\n\n100\\. Hass C.J., Collins M.A., Juncos J.L. Resistance training with creatine\nmonohydrate improves upper-body strength in patients with Parkinson disease: A\nrandomized trial. Neurorehabil. Neural Repair. 2007;21:107\u2013115. doi:\n10.1177/1545968306293449. [PubMed] [CrossRef] [Google Scholar]\n\n101\\. Kieburtz K., Tilley B.C., Elm J.J., Babcock D., Hauser R., Ross G.W.,\nAugustine A.H., Augustine E.U., Aminoff M.J., Bodis-Wollner I.G., et al.\nEffect of creatine monohydrate on clinical progression in patients with\nParkinson disease: A randomized clinical trial. JAMA. 2015;313:584\u2013593. doi:\n10.1001/jama.2015.120. [PMC free article] [PubMed] [CrossRef] [Google Scholar]\n\n102\\. Kessler R.C., Wai T.C., Demler O., Walters E.E. Prevalence, severity,\nand comorbidity of 12-month DSM-IV disorders in the National Comorbidity\nSurvey Replication. Arch. Gen. Psychiatry. 2005;62:617\u2013627. doi:\n10.1001/archpsyc.62.6.617. [PMC free article] [PubMed] [CrossRef] [Google\nScholar]\n\n103\\. Palay J., Taillieu T.L., Afifi T.O., Turner S., Bolton J.M., Enns M.W.,\nSmith M., Lesage A., Bakal J.A., Rush B., et al. Prevalence of Mental\nDisorders and Suicidality in Canadian Provinces. Can. J. Psychiatry.\n2019;64:761\u2013769. doi: 10.1177/0706743719878987. [PMC free article] [PubMed]\n[CrossRef] [Google Scholar]\n\n104\\. Masand P.S. Tolerability and adherence issues in antidepressant therapy.\nClin. Ther. 2003;25:2289\u20132304. doi: 10.1016/S0149-2918(03)80220-5. [PubMed]\n[CrossRef] [Google Scholar]\n\n105\\. Nemeroff C.B. Prevalence and management of treatment-resistant\ndepression. J. Clin. Psychiatry. 2007;68:17\u201325. doi: 10.4088/JCP.0707e17.\n[PubMed] [CrossRef] [Google Scholar]\n\n106\\. Usala T., Clavenna A., Zuddas A., Bonati M. Randomised controlled trials\nof selective serotonin reuptake inhibitors in treating depression in children\nand adolescents: A systematic review and meta-analysis. Eur.\nNeuropsychopharmacol. 2008;18:62\u201373. doi: 10.1016/j.euroneuro.2007.06.001.\n[PubMed] [CrossRef] [Google Scholar]\n\n107\\. Doran C.M., Kinchin I. A review of the economic impact of mental\nillness. Aust. Heal. Rev. 2019;43:43\u201348. doi: 10.1071/AH16115. [PubMed]\n[CrossRef] [Google Scholar]\n\n108\\. Fons C., Campistol J. Creatine Defects and Central Nervous System.\nSemin. Pediatr. Neurol. 2016;23:285\u2013289. doi: 10.1016/j.spen.2016.11.003.\n[PubMed] [CrossRef] [Google Scholar]\n\n109\\. Faulkner P., Paioni S.L., Kozhuharova P., Orlov N., Lythgoe D.J., Daniju\nY., Morgenroth E., Barker H., Allen P. Relationship between depression,\nprefrontal creatine and grey matter volume. J. Psychopharmacol.\n2021;35:1464\u20131472. doi: 10.1177/02698811211050550. [PMC free article] [PubMed]\n[CrossRef] [Google Scholar]\n\n110\\. Allen P.J., D\u2019Anci K.E., Kanarek R.B., Renshaw P.F. Sex-specific\nantidepressant effects of dietary creatine with and without sub-acute\nfluoxetine in rats. Pharmacol. Biochem. Behav. 2012;101:588\u2013601. doi:\n10.1016/j.pbb.2012.03.005. [PMC free article] [PubMed] [CrossRef] [Google\nScholar]\n\n111\\. Bakian A.V., Huber R.S., Scholl L., Renshaw P.F., Kondo D. Dietary\ncreatine intake and depression risk among U.S. adults. Transl. Psychiatry.\n2020;10:52. doi: 10.1038/s41398-020-0741-x. [PMC free article] [PubMed]\n[CrossRef] [Google Scholar]\n\n112\\. Allen P.J., D\u2019Anci K.E., Kanarek R.B., Renshaw P.F. Chronic creatine\nsupplementation alters depression-like behavior in rodents in a sex-dependent\nmanner. Neuropsychopharmacology. 2010;35:534\u2013546. doi: 10.1038/npp.2009.160.\n[PMC free article] [PubMed] [CrossRef] [Google Scholar]\n\n113\\. Allen P.J., Debold J.F., Rios M., Kanarek R.B. Chronic high-dose\ncreatine has opposing effects on depression-related gene expression and\nbehavior in intact and sex hormone-treated gonadectomized male and female\nrats. Pharmacol. Biochem. Behav. 2015;130:22\u201333. doi:\n10.1016/j.pbb.2014.12.014. [PMC free article] [PubMed] [CrossRef] [Google\nScholar]\n\n114\\. Kanekar S., Ettaro R., Hoffman M.D., Ombach H.J., Brown J., Lynch C.,\nSheth C.S., Renshaw P.F. Sex-Based Impact of Creatine Supplementation on\nDepressive Symptoms, Brain Serotonin and SSRI Efficacy in an Animal Model of\nTreatment-Resistant Depression. Int. J. Mol. Sci. 2021;22:8195. doi:\n10.3390/ijms22158195. [PMC free article] [PubMed] [CrossRef] [Google Scholar]\n\n115\\. Okwuofu E.O., Ogundepo G.E., Akhigbemen A.M., Abiola A.L., Ozolua R.I.,\nIgbe I., Chinazamoku O. Creatine attenuates seizure severity, anxiety and\ndepressive-like behaviors in pentylenetetrazole kindled mice. Metab. Brain\nDis. 2021;36:571\u2013579. doi: 10.1007/s11011-021-00684-w. [PubMed] [CrossRef]\n[Google Scholar]\n\n116\\. Rosa J.M., Pazini F.L., Cunha M.P., Colla A.R.S., Manosso L.M., Mancini\nG., Souza A.C.G., de Bem A.F., Prediger R.D., Rodrigues A.L.S. Antidepressant\neffects of creatine on amyloid \u03b2 1-40-treated mice: The role of GSK-3\u03b2/Nrf 2\npathway. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2018;86:270\u2013278. doi:\n10.1016/j.pnpbp.2018.05.001. [PubMed] [CrossRef] [Google Scholar]\n\n117\\. Warrington T.P., Bostwick J.M. Psychiatric adverse effects of\ncorticosteroids. Mayo Clin. Proc. 2006;81:1361\u20131367. doi: 10.4065/81.10.1361.\n[PubMed] [CrossRef] [Google Scholar]\n\n118\\. Pazini F.L., Cunha M.P., Azevedo D., Rosa J.M., Colla A., de Oliveira\nJ., Ramos-Hryb A.B., Brocardo P.S., Gil-Mohapel J., Rodrigues A.L.S. Creatine\nPrevents Corticosterone-Induced Reduction in Hippocampal Proliferation and\nDifferentiation: Possible Implication for Its Antidepressant Effect. Mol.\nNeurobiol. 2017;54:6245\u20136260. doi: 10.1007/s12035-016-0148-0. [PubMed]\n[CrossRef] [Google Scholar]\n\n119\\. Pazini F.L., Rosa J.M., Camargo A., Fraga D.B., Moretti M., Siteneski\nA., Rodrigues A.L.S. mTORC1-dependent signaling pathway underlies the rapid\neffect of creatine and ketamine in the novelty-suppressed feeding test. Chem.\nBiol. Interact. 2020;332:109281. doi: 10.1016/j.cbi.2020.109281. [PubMed]\n[CrossRef] [Google Scholar]\n\n120\\. Amital D., Vishne T., Rubinow A., Levine J. Observed effects of creatine\nmonohydrate in a patient with depression and fibromyalgia. Am. J. Psychiatry.\n2006;163:1840\u20131841. doi: 10.1176/ajp.2006.163.10.1840b. [PubMed] [CrossRef]\n[Google Scholar]\n\n121\\. Lyoo I.K., Yoon S., Kim T.-S., Hwang J., Kim J.E., Won W., Bae S.,\nRenshaw P.F. A Randomized, Double-Blind Placebo-Controlled Trial of Oral\nCreatine Monohydrate Augmentation for Enhanced Response to a Selective\nSerotonin Reuptake Inhibitor in Women with Major Depressive Disorder. Am. J.\nPsychiatry. 2012;169:937\u2013945. doi: 10.1176/appi.ajp.2012.12010009. [PMC free\narticle] [PubMed] [CrossRef] [Google Scholar]\n\n122\\. Roitman S., Green T., Osher Y., Karni N., Levine J. Creatine monohydrate\nin resistant depression: A preliminary study. Bipolar Disord. 2007;9:754\u2013758.\ndoi: 10.1111/j.1399-5618.2007.00532.x. [PubMed] [CrossRef] [Google Scholar]\n\n123\\. Toniolo R., Fernandes F., Silva M., Dias R., Lafer B. Cognitive effects\nof creatine monohydrate adjunctive therapy in patients with bipolar\ndepression: Results from a randomized, double-blind, placebo-controlled trial.\nJ. Affect. Disord. 2017;224:69\u201375. doi: 10.1016/j.jad.2016.11.029. [PubMed]\n[CrossRef] [Google Scholar]\n\n124\\. Toniolo R.A., Silva M., de Brito Ferreira Fernandes F., de Mello\nSiqueira Amaral J.A., da Silva Dias R., Lafer B. A randomized, double-blind,\nplacebo-controlled, proof-of-concept trial of creatine monohydrate as\nadjunctive treatment for bipolar depression. J. Neural Transm.\n2018;125:247\u2013257. doi: 10.1007/s00702-017-1817-5. [PMC free article] [PubMed]\n[CrossRef] [Google Scholar]\n\n125\\. Kious B.M., Kondo D.G., Renshaw P.F. Creatine for the Treatment of\nDepression. Biomolecules. 2019;9:406. doi: 10.3390/biom9090406. [PMC free\narticle] [PubMed] [CrossRef] [Google Scholar]\n\n126\\. Nemets B., Levine J. A pilot dose-finding clinical trial of creatine\nmonohydrate augmentation to SSRIs/SNRIs/NASA antidepressant treatment in major\ndepression. Int. Clin. Psychopharmacol. 2013;28:127\u2013133. doi:\n10.1097/YIC.0b013e32835ff20f. [PubMed] [CrossRef] [Google Scholar]\n\n127\\. Watson P. PTSD as a Public Mental Health Priority. Curr. Psychiatry Rep.\n2019;21:61. doi: 10.1007/s11920-019-1032-1. [PubMed] [CrossRef] [Google\nScholar]\n\n128\\. Coplan J.D., Mathew S.J., Mao X., Smith E.L.P., Hof P.R., Coplan P.M.,\nRosenblum L.A., Gorman J.M., Shungu D.C. Decreased choline and creatine\nconcentrations in centrum semiovale in patients with generalized anxiety\ndisorder: Relationship to IQ and early trauma. Psychiatry Res. 2006;147:27\u201339.\ndoi: 10.1016/j.pscychresns.2005.12.011. [PubMed] [CrossRef] [Google Scholar]\n\n129\\. Schuff N., Neylan T.C., Fox-Bosetti S., Lenoci M., Samuelson K.W.,\nStudholme C., Kornak J., Marmar C.R., Weiner M.W. Abnormal N-acetylaspartate\nin hippocampus and anterior cingulate in posttraumatic stress disorder.\nPsychiatry Res. 2008;162:147\u2013157. doi: 10.1016/j.pscychresns.2007.04.011. [PMC\nfree article] [PubMed] [CrossRef] [Google Scholar]\n\n130\\. Villarreal G., Petropoulos H., Hamilton D.A., Rowland L.M., Horan W.P.,\nGriego J.A., Moreshead M., Hart B.L., Brooks W.M. Proton magnetic resonance\nspectroscopy of the hippocampus and occipital white matter in PTSD:\nPreliminary results. Can. J. Psychiatry. 2002;47:666\u2013670. doi:\n10.1177/070674370204700709. [PubMed] [CrossRef] [Google Scholar]\n\n131\\. Amital D., Vishne T., Roitman S., Kotler M., Levine J. Open study of\ncreatine monohydrate in treatment-resistant posttraumatic stress disorder. J.\nClin. Psychiatry. 2006;67:836\u2013837. doi: 10.4088/JCP.v67n0521c. [PubMed]\n[CrossRef] [Google Scholar]\n\n132\\. Ashbaugh A., McGrew C. The Role of Nutritional Supplements in Sports\nConcussion Treatment. Curr. Sports Med. Rep. 2016;15:16\u201319. doi:\n10.1249/JSR.0000000000000219. [PubMed] [CrossRef] [Google Scholar]\n\n133\\. Ainsley Dean P.J., Arikan G., Opitz B., Sterr A. Potential for use of\ncreatine supplementation following mild traumatic brain injury. Concussion.\n2017;2:CNC34. doi: 10.2217/cnc-2016-0016. [PMC free article] [PubMed]\n[CrossRef] [Google Scholar]\n\n134\\. Cassol G., Godinho D.B., de Zorzi V.N., Farinha J.B., Della-Pace I.D.,\nde Carvalho Gon\u00e7alves M., Oliveira M.S., Furian A.F., Fighera M.R., Royes\nL.F.F. Potential therapeutic implications of ergogenic compounds on\npathophysiology induced by traumatic brain injury: A narrative review. Life\nSci. 2019;233:116684. doi: 10.1016/j.lfs.2019.116684. [PubMed] [CrossRef]\n[Google Scholar]\n\n135\\. Pender S.C., Smith A.M., Finnoff J.T., Huston J., Stuart M.J.\nConcussions in Ice Hockey\u2014Moving Toward Objective Diagnoses and Point-of-care\nTreatment: A Review. Curr. Sports Med. Rep. 2020;19:380\u2013386. doi:\n10.1249/JSR.0000000000000752. [PubMed] [CrossRef] [Google Scholar]\n\n136\\. Kreider R.B., Stout J.R. Creatine in Health and Disease. Nutrients.\n2021;13:447. doi: 10.3390/nu13020447. [PMC free article] [PubMed] [CrossRef]\n[Google Scholar]\n\n137\\. Giza C.C., Hovda D.A. The new neurometabolic cascade of concussion.\nNeurosurgery. 2014;75:S24\u2013S33. doi: 10.1227/NEU.0000000000000505. [PMC free\narticle] [PubMed] [CrossRef] [Google Scholar]\n\n138\\. Barkhoudarian G., Hovda D.A., Giza C.C. The Molecular Pathophysiology of\nConcussive Brain Injury\u2014An Update. Phys. Med. Rehabil. Clin. N. Am.\n2016;27:373\u2013393. doi: 10.1016/j.pmr.2016.01.003. [PubMed] [CrossRef] [Google\nScholar]\n\n139\\. Yoshino A., Hovda D.A., Kawamata T., Katayama Y., Becker D.P. Dynamic\nchanges in local cerebral glucose utilization following cerebral conclusion in\nrats: Evidence of a hyper- and subsequent hypometabolic state. Brain Res.\n1991;561:106\u2013119. doi: 10.1016/0006-8993(91)90755-K. [PubMed] [CrossRef]\n[Google Scholar]\n\n140\\. Wang Y., Bartels H.M., Nelson L.D. A Systematic Review of ASL Perfusion\nMRI in Mild TBI. Neuropsychol. Rev. 2020:1\u201332. doi:\n10.1007/s11065-020-09451-7. [PMC free article] [PubMed] [CrossRef] [Google\nScholar]\n\n141\\. Signoretti S., Di Pietro V., Vagnozzi R., Lazzarino G., Amorini A.M.,\nBelli A., D\u2019Urso S., Tavazzi B. Transient alterations of creatine, creatine\nphosphate, N-acetylaspartate and high-energy phosphates after mild traumatic\nbrain injury in the rat. Mol. Cell. Biochem. 2010;333:269\u2013277. doi:\n10.1007/s11010-009-0228-9. [PubMed] [CrossRef] [Google Scholar]\n\n142\\. Vagnozzi R., Signoretti S., Floris R., Marziali S., Manara M., Amorini\nA.M., Belli A., Di Pietro V., D\u2019Urso S., Pastore F.S., et al. Decrease in\nN-acetylaspartate following concussion may be coupled to decrease in creatine.\nJ. Head Trauma Rehabil. 2013;28:284\u2013292. doi: 10.1097/HTR.0b013e3182795045.\n[PubMed] [CrossRef] [Google Scholar]\n\n143\\. Sakellaris G., Kotsiou M., Tamiolaki M., Kalostos G., Tsapaki E.,\nSpanaki M., Spilioti M., Charissis G., Evangeliou A. Prevention of\ncomplications related to traumatic brain injury in children and adolescents\nwith creatine administration: An open label randomized pilot study. J. Trauma.\n2006;61:322\u2013329. doi: 10.1097/01.ta.0000230269.46108.d5. [PubMed] [CrossRef]\n[Google Scholar]\n\n144\\. Sakellaris G., Nasis G., Kotsiou M., Tamiolaki M., Charissis G.,\nEvangeliou A. Prevention of traumatic headache, dizziness and fatigue with\ncreatine administration. A pilot study. Acta Paediatr. 2008;97:34. doi:\n10.1111/j.1651-2227.2007.00529.x. [PMC free article] [PubMed] [CrossRef]\n[Google Scholar]\n\n145\\. Sakellaris G., Partalis N., Nasis G., Kotsiou M., Tamiolaki M.,\nBouloukaki E., Evangeliou A. Outcome of Traumatic Dysarthria and Lingual\nProblems of Understanding with Creatine Administration. An Open Label\nRandomized Pilot Study. J. Trauma Treat. 2012;1:120. doi:\n10.4172/2167-1222.1000120. [CrossRef] [Google Scholar]\n\n146\\. Sullivan P., Geiger J., Mattson M., Scheff S. Dietary supplement\ncreatine protects against traumatic brain injury. Ann. Neurol.\n2000;48:723\u2013729. doi: 10.1002/1531-8249(200011)48:5<723::AID-ANA5>3.0.CO;2-W.\n[PubMed] [CrossRef] [Google Scholar]\n\n147\\. Scheff S.W., Dhillon H.S. Creatine-enhanced diet alters levels of\nlactate and free fatty acids after experimental brain injury. Neurochem. Res.\n2004;29:469\u2013479. doi: 10.1023/B:NERE.0000013753.22615.59. [PubMed] [CrossRef]\n[Google Scholar]\n\n148\\. Masse I., Moquin L., Bouchard C., Gratton A., De Beaumont L. Efficacy of\nprophylactic versus therapeutic administration of the NMDA receptor antagonist\nMK-801 on the acute neurochemical response to a concussion in a rat model\ncombining force and rotation. J. Neurosurg. 2021;1:1\u201310. doi:\n10.3171/2021.3.JNS204163. [PubMed] [CrossRef] [Google Scholar]\n\n149\\. Genius J., Geiger J., Bender A., M\u00f6ller H.J., Klopstock T., Rujescu D.\nCreatine protects against excitoxicity in an in vitro model of\nneurodegeneration. PLoS ONE. 2012;7:e30554. doi: 10.1371/journal.pone.0030554.\n[PMC free article] [PubMed] [CrossRef] [Google Scholar]\n\n150\\. Saraiva A.L.L., Ferreira A.P.O., Silva L.F.A., Hoffmann M.S., Dutra\nF.D., Furian A.F., Oliveira M.S., Fighera M.R., Royes L.F.F. Creatine reduces\noxidative stress markers but does not protect against seizure susceptibility\nafter severe traumatic brain injury. Brain Res. Bull. 2012;87:180\u2013186. doi:\n10.1016/j.brainresbull.2011.10.010. [PubMed] [CrossRef] [Google Scholar]\n\n  * Abstract\n  * 1\\. Introduction\n  * 2\\. Creatine and Guanidinoacetic Acid (GAA) Supplementation on Brain Creatine and Phophorylcreatine (PCr)\n  * 3\\. Creatine and Cognitive Function\n  * 4\\. Creatine for Neurodegenerative Diseases\n  * 5\\. Creatine and Mental Health\n  * 6\\. Creatine for Concussion and Traumatic Brain Injury (TBI)\n  * 7\\. Conclusions and Future Directions\n  * Author Contributions\n  * Funding\n  * Conflicts of Interest\n  * Footnotes\n  * References\n\nArticles from Nutrients are provided here courtesy of Multidisciplinary\nDigital Publishing Institute (MDPI)\n\n1\\. Allen P.J. Creatine metabolism and psychiatric disorders: Does creatine\nsupplementation have therapeutic value? Neurosci. Biobehav. Rev. 2012;36:1462.\ndoi: 10.1016/j.neubiorev.2012.03.005. [PMC free article] [PubMed] [CrossRef]\n[Google Scholar] [Ref list]\n\n2\\. Snow W., Cadonic C., Cortes-Perez C., Roy Chowdhury S., Djordjevic J.,\nThomson E., Bernstein M., Suh M., Fernyhough P., Albensi B. Chronic dietary\ncreatine enhances hippocampal-dependent spatial memory, bioenergetics, and\nlevels of plasticity-related proteins associated with NF-\u03baB. Learn. Mem.\n2018;25:54\u201366. doi: 10.1101/lm.046284.117. [PMC free article] [PubMed]\n[CrossRef] [Google Scholar] [Ref list]\n\n3\\. Forbes S., Candow D., Ferreira L., Souza-Junior T. Effects of creatine\nsupplementation on properties of muscle, bone, and brain function in older\nadults: A narrative review. J. Diet. Suppl. 2021:1\u201318. doi:\n10.1080/19390211.2021.1877232. [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n4\\. Ricci T., Forbes S.C., Candow D.G. Creatine supplementation: Practical\nstrategies and considerations for mixed martial arts. J. Exerc. Nutr.\n2020;3:s2. [Google Scholar] [Ref list]\n\n5\\. Roschel H., Gualano B., Ostojic S.M., Rawson E.S. Creatine Supplementation\nand Brain Health. Nutrients. 2021;13:586. doi: 10.3390/nu13020586. [PMC free\narticle] [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n6\\. Wyss M., Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol.\nRev. 2000;80:1107\u20131213. doi: 10.1152/physrev.2000.80.3.1107. [PubMed]\n[CrossRef] [Google Scholar] [Ref list]\n\n7\\. Wallimann T., Dolder M., Schlattner U., Eder M., Hornemann T., Kraft T.,\nStolz M. Creatine kinase: An enzyme with a central role in cellular energy\nmetabolism. MAGMA. 1998;6:116\u2013119. doi: 10.1007/BF02660927. [PubMed]\n[CrossRef] [Google Scholar] [Ref list]\n\n8\\. Fernandes-Pires G., Braissant O. Current and potential new treatment\nstrategies for creatine deficiency syndromes. Mol. Genet. Metab.\n2022;135:15\u201326. doi: 10.1016/j.ymgme.2021.12.005. [PubMed] [CrossRef] [Google\nScholar] [Ref list]\n\n9\\. Harris R., S\u00f6derlund K., Hultman E. Elevation of creatine in resting and\nexercised muscle of normal subjects by creatine supplementation. Clin. Sci.\n1992;83:367\u2013374. doi: 10.1042/cs0830367. [PubMed] [CrossRef] [Google Scholar]\n[Ref list]\n\n10\\. Hultman E., Soderlund K., Timmons J.A., Cederblad G., Greenhaff P.L.\nMuscle Creatine Loading in Men. J. Appl. Physiol. 1996;81:232\u2013237. doi:\n10.1152/jappl.1996.81.1.232. [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n11\\. Kreider R., Kalman D., Antonio J., Ziegenfuss T., Wildman R., Collins R.,\nCandow D., Kleiner S., Almada A., Lopez H. International Society of Sports\nNutrition position stand: Safety and efficacy of creatine supplementation in\nexercise, sport, and medicine. J. Int. Soc. Sports Nutr. 2017;14:18. doi:\n10.1186/s12970-017-0173-z. [PMC free article] [PubMed] [CrossRef] [Google\nScholar] [Ref list]\n\n12\\. Robinson T.M., Sewell D.A., Hultman E., Greenhaff P.L. Role of submaximal\nexercise in promoting creatine and glycogen accumulation in human skeletal\nmuscle. J. Appl. Physiol. 1999;87:598\u2013604. doi: 10.1152/jappl.1999.87.2.598.\n[PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n13\\. Steenge G.R., Lambourne J., Casey A., Macdonald I.A., Greenhaff P.L.\nStimulatory effect of insulin on creatine accumulation in human skeletal\nmuscle. Am. J. Physiol. Endocrinol. Metab. 1998;275:E974\u2013E979. doi:\n10.1152/ajpendo.1998.275.6.E974. [PubMed] [CrossRef] [Google Scholar] [Ref\nlist]\n\n14\\. Green A., Hultman E., Macdonald I., Sewell D., Greenhaff P. Carbohydrate\ningestion augments skeletal muscle creatine accumulation during creatine\nsupplementation in humans. Am. J. Physiol. 1996;271:E821\u2013E826. doi:\n10.1152/ajpendo.1996.271.5.E821. [PubMed] [CrossRef] [Google Scholar] [Ref\nlist]\n\n15\\. Steenge G.R., Simpson E.J., Greenhaff P.L. Protein- and carbohydrate-\ninduced augmentation of whole body creatine retention in humans. J. Appl.\nPhysiol. 2000;89:1165\u20131171. doi: 10.1152/jappl.2000.89.3.1165. [PubMed]\n[CrossRef] [Google Scholar] [Ref list]\n\n16\\. Burke D.G., Chilibeck P.D., Parise G., Tarnopolsky M.A., Candow D.G.\nEffect of alpha-lipoic acid combined with creatine monohydrate on human\nskeletal muscle creatine and phosphagen concentration. Int. J. Sport Nutr.\nExerc. Metab. 2003;13:294\u2013302. doi: 10.1123/ijsnem.13.3.294. [PubMed]\n[CrossRef] [Google Scholar] [Ref list]\n\n17\\. Avgerinos K.I., Spyrou N., Bougioukas K.I., Kapogiannis D. Effects of\ncreatine supplementation on cognitive function of healthy individuals: A\nsystematic review of randomized controlled trials. Exp. Gerontol.\n2018;108:173. doi: 10.1016/j.exger.2018.04.013. [PMC free article] [PubMed]\n[CrossRef] [Google Scholar] [Ref list]\n\n18\\. Dolan E., Gualano B., Rawson E.S. Beyond muscle: The effects of creatine\nsupplementation on brain creatine, cognitive processing, and traumatic brain\ninjury. Eur. J. Sport Sci. 2019;19:1\u201314. doi: 10.1080/17461391.2018.1500644.\n[PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n19\\. Dechent P., Pouwels P.J.W., Wilken B., Hanefeld F., Frahm J. Increase of\ntotal creatine in human brain after oral supplementation of creatine-\nmonohydrate. Am. J. Physiol. Regul. Integr. Comp. Physiol. 1999;46:R698\u2013R704.\ndoi: 10.1152/ajpregu.1999.277.3.R698. [PubMed] [CrossRef] [Google Scholar]\n[Ref list]\n\n20\\. Pan J.W., Takahashi K. Cerebral energetic effects of creatine\nsupplementation in humans. Am. J. Physiol. Regul. Integr. Comp. Physiol.\n2007;292:R1745. doi: 10.1152/ajpregu.00717.2006. [PMC free article] [PubMed]\n[CrossRef] [Google Scholar] [Ref list]\n\n21\\. Kondo D.G., Sung Y.H., Hellem T.L., Fiedler K.K., Shi X., Jeong E.K.,\nRenshaw P.F. Open-label adjunctive creatine for female adolescents with SSRI-\nresistant major depressive disorder: A 31-phosphorus magnetic resonance\nspectroscopy study. J. Affect. Disord. 2011;135:354\u2013361. doi:\n10.1016/j.jad.2011.07.010. [PMC free article] [PubMed] [CrossRef] [Google\nScholar] [Ref list]\n\n22\\. Hellem T.L., Sung Y.-H., Shi X.-F., Pett M.A., Latendresse G., Morgan J.,\nHuber R.S., Kuykendall D., Lundberg K.J., Renshaw P.F. Creatine as a Novel\nTreatment for Depression in Females Using Methamphetamine: A Pilot Study. J.\nDual Diagn. 2015;11:189\u2013202. doi: 10.1080/15504263.2015.1100471. [PMC free\narticle] [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n23\\. Turner C.E., Byblow W.D., Gant N. Creatine Supplementation Enhances\nCorticomotor Excitability and Cognitive Performance during Oxygen Deprivation.\nJ. Neurosci. 2015;35:1773. doi: 10.1523/JNEUROSCI.3113-14.2015. [PMC free\narticle] [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n24\\. Solis M., Artioli G., Otaduy M., Leite C., Arruda W., Veiga R., Gualano\nB. Effect of age, diet, and tissue type on PCr response to creatine\nsupplementation. J. Appl. Physiol. 2017;123:407\u2013414. doi:\n10.1152/japplphysiol.00248.2017. [PubMed] [CrossRef] [Google Scholar] [Ref\nlist]\n\n25\\. Lyoo I.K., Kong S.W., Sung S.M., Hirashima F., Parow A., Hennen J., Cohen\nB.M., Renshaw P.F. Multinuclear magnetic resonance spectroscopy of high-energy\nphosphate metabolites in human brain following oral supplementation of\ncreatine-monohydrate. Psychiatry Res. 2003;123:87\u2013100. doi:\n10.1016/S0925-4927(03)00046-5. [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n26\\. Turner C.E., Russell B.R., Gant N. Comparative quantification of dietary\nsupplemented neural creatine concentrations with (1)H-MRS peak fitting and\nbasis spectrum methods. Magn. Reson. Imaging. 2015;33:1163\u20131167. doi:\n10.1016/j.mri.2015.06.018. [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n27\\. Wilkinson I.D., Mitchel N., Breivik S., Greenwood P., Griffiths P.D.,\nWinter E.M., Van Beek E.J.R. Effects of creatine supplementation on cerebral\nwhite matter in competitive sportsmen. Clin. J. Sport Med. 2006;16:63\u201367. doi:\n10.1097/01.jsm.0000176372.67398.c8. [PubMed] [CrossRef] [Google Scholar] [Ref\nlist]\n\n28\\. Merege-Filho C.A.A., Otaduy M.C.G., de S\u00e1-Pinto A.L., de Oliveira M.O.,\nde Souza Gon\u00e7alves L., Hayashi A.P.T., Roschel H., Pereira R.M.R., Silva C.A.,\nBrucki S.M.D., et al. Does brain creatine content rely on exogenous creatine\nin healthy youth? A proof-of-principle study. Appl. Physiol. Nutr. Metab.\n2016;42:128\u2013134. doi: 10.1139/apnm-2016-0406. [PubMed] [CrossRef] [Google\nScholar] [Ref list]\n\n29\\. Braissant O., Bachmann C., Henry H. Expression and function of AGAT, GAMT\nand CT1 in the mammalian brain. Subcell. Biochem. 2007;46:67\u201381. doi:\n10.1007/978-1-4020-6486-9_4. [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n30\\. Andres R.H., Ducray A.D., Schlattner U., Wallimann T., Widmer H.R.\nFunctions and effects of creatine in the central nervous system. Brain Res.\nBull. 2008;76:329\u2013343. doi: 10.1016/j.brainresbull.2008.02.035. [PubMed]\n[CrossRef] [Google Scholar] [Ref list]\n\n31\\. B\u00e9ard E., Braissant O. Synthesis and transport of creatine in the CNS:\nImportance for cerebral functions. J. Neurochem. 2010;115:297\u2013313. doi:\n10.1111/j.1471-4159.2010.06935.x. [PubMed] [CrossRef] [Google Scholar] [Ref\nlist]\n\n32\\. Salomons G.S., Van Dooren S.J.M., Verhoeven N.M., Marsden D., Schwartz\nC., Cecil K.M., DeGrauw T.J., Jakobs C. X-linked creatine transporter defect:\nAn overview. J. Inherit. Metab. Dis. 2003;26:309\u2013318. doi:\n10.1023/A:1024405821638. [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n33\\. Jagim A.R., Kerksick C.M. Creatine Supplementation in Children and\nAdolescents. Nutrients. 2021;13:664. doi: 10.3390/nu13020664. [PMC free\narticle] [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n34\\. St\u00f6ckler S., Holzbach U., Hanefeld F., Marquardt I., Helms G., Requar\nT.M., Hanicke W., Frahm J. Creatine deficiency in the brain: A new, treatable\ninborn error of metabolism. Pediatr. Res. 1994;36:409\u2013413. doi:\n10.1203/00006450-199409000-00023. [PubMed] [CrossRef] [Google Scholar] [Ref\nlist]\n\n35\\. Borsook M., Billig H., Golseth J. Betaine and glycocyamine in the\ntreatment of disability resulting from acute anterior poliomyelitis. Ann.\nWest. Med. Surg. 1952;6:423\u2013427. [PubMed] [Google Scholar] [Ref list]\n\n36\\. Fallis B.D., Lam R.L. Betaine and glycocyamine therapy for the chronic\nresiduals of poliomyelitis. J. Am. Med. Assoc. 1952;150:851\u2013853. doi:\n10.1001/jama.1952.03680090015007. [PubMed] [CrossRef] [Google Scholar] [Ref\nlist]\n\n37\\. Aldes J. Glycocyamine betaine as an adjunct in the treatment of\nneuromuscular disease patients. J. Ark. Med. Soc. 1957;54:186\u2013194. [PubMed]\n[Google Scholar] [Ref list]\n\n38\\. Watkins A.L. Betaine and glycocyamine in the treatment of poliomyelitis.\nN. Engl. J. Med. 1953;248:621\u2013623. doi: 10.1056/NEJM195304092481501. [PubMed]\n[CrossRef] [Google Scholar] [Ref list]\n\n39\\. Liveksedge L.A. Glycocyamine and betaine in motor-neurone disease.\nLancet. 1956;271:1136\u20131138. doi: 10.1016/S0140-6736(56)90154-4. [PubMed]\n[CrossRef] [Google Scholar] [Ref list]\n\n40\\. McBreairty L.E., Robinson J.L., Furlong K.R., Brunton J.A., Bertolo R.F.\nGuanidinoacetate is more effective than creatine at enhancing tissue creatine\nstores while consequently limiting methionine availability in Yucatan\nminiature pigs. PLoS ONE. 2015;10:e0131563. doi: 10.1371/journal.pone.0131563.\n[PMC free article] [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n41\\. Ostojic S.M., Ostojic J., Drid P., Vranes M. Guanidinoacetic acid versus\ncreatine for improved brain and muscle creatine levels: A superiority pilot\ntrial in healthy men. Appl. Physiol. Nutr. Metab. 2016;41:1005\u20131007. doi:\n10.1139/apnm-2016-0178. [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n42\\. Ostojic S.M., Ostojic J., Drid P., Vranes M., Jovanov P. Dietary\nguanidinoacetic acid increases brain creatine levels in healthy men.\nNutrition. 2017;33:149\u2013156. doi: 10.1016/j.nut.2016.06.001. [PubMed]\n[CrossRef] [Google Scholar] [Ref list]\n\n43\\. Semeredi S., Stajer V., Ostojic J., Vranes M., Ostojic S.M.\nGuanidinoacetic acid with creatine compared with creatine alone for tissue\ncreatine content, hyperhomocysteinemia, and exercise performance: A\nrandomized, double-blind superiority trial. Nutrition. 2019;57:162\u2013166. doi:\n10.1016/j.nut.2018.04.009. [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n44\\. Ostojic S.M. Guanidinoacetic acid loading for improved location-specific\nbrain creatine. Clin. Nutr. 2021;40:324\u2013326. doi: 10.1016/j.clnu.2020.05.003.\n[PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n45\\. Robinson J.L., McBreairty L.E., Ryan R.A., Randunu R., Walsh C.J., Martin\nG.M., Brunton J.A., Bertolo R.F. Effects of supplemental creatine and\nguanidinoacetic acid on spatial memory and the brain of weaned Yucatan\nminiature pigs. PLoS ONE. 2020;15:e0226806. doi: 10.1371/journal.pone.0226806.\n[PMC free article] [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n46\\. Ostojic S.M., Stojanovic M., Drid P., Hoffman J.R., Sekulic D., Zenic N.\nSupplementation with Guanidinoacetic Acid in Women with Chronic Fatigue\nSyndrome. Nutrients. 2016;8:72. doi: 10.3390/nu8020072. [PMC free article]\n[PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n47\\. Seper V., Korovljev D., Todorovic N., Stajer V., Ostojic J., Nesic N.,\nOstojic S.M. Guanidinoacetate-Creatine Supplementation Improves Functional\nPerformance and Muscle and Brain Bioenergetics in the Elderly: A Pilot Study.\nAnn. Nutr. Metab. 2021;77:244\u2013247. doi: 10.1159/000518499. [PubMed] [CrossRef]\n[Google Scholar] [Ref list]\n\n48\\. Ostojic S.M. Tackling guanidinoacetic acid for advanced cellular\nbioenergetics. Nutrition. 2017;34:55\u201357. doi: 10.1016/j.nut.2016.09.010.\n[PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n49\\. Takahashi H., Arai B., Koshino C. Effects of guanidinoacetic acid, gamma-\nguanidinobutyric acid and gamma-guanidinobutyryl-methylester on the mammalian\ncerebral cortex. Jpn. J. Physiol. 1961;11:403\u2013409. doi:\n10.2170/jjphysiol.11.403. [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n50\\. Neu A., Neuhoff H., Trube G., Fehr S., Ullrich K., Roeper J., Isbrandt D.\nActivation of GABA(A) receptors by guanidinoacetate: A novel\npathophysiological mechanism. Neurobiol. Dis. 2002;11:298\u2013307. doi:\n10.1006/nbdi.2002.0547. [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n51\\. Zugno A.I., Stefanello F.M., Streck E.L., Calcagnotto T., Wannmacher\nC.M.D., Wajner M., Wyse A.T.S. Inhibition of Na^+, K^+-ATPase activity in rat\nstriatum by guanidinoacetate. Int. J. Dev. Neurosci. 2003;21:183\u2013189. doi:\n10.1016/S0736-5748(03)00038-8. [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n52\\. Zugno A.I., Scherer E.B.S., Schuck P.F., Oliveira D.L., Wofchuk S.,\nWannmacher C.M.D., Wajner M., Wyse A.T.S. Intrastriatal administration of\nguanidinoacetate inhibits Na^+, K^+-ATPase and creatine kinase activities in\nrat striatum. Metab. Brain Dis. 2006;21:41\u201350. doi: 10.1007/s11011-006-9003-8.\n[PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n53\\. Zugno A.I., Scherer E.B.S., Mattos C., Ribeiro C.A.J., Wannmacher C.M.D.,\nWajner M., Wyse A.T.S. Evidence that the inhibitory effects of\nguanidinoacetate on the activities of the respiratory chain, Na^+, K^+-ATPase\nand creatine kinase can be differentially prevented by taurine and vitamins E\nand C administration in rat striatum in vivo. Biochim. Biophys. Acta.\n2007;1772:563\u2013569. doi: 10.1016/j.bbadis.2007.02.005. [PubMed] [CrossRef]\n[Google Scholar] [Ref list]\n\n54\\. Zugno A.I., Oliveira D.L., Scherer E.B.S., Wajner M., Wofchuk S., Wyse\nA.T.S. Guanidinoacetate inhibits glutamate uptake in rat striatum of rats at\ndifferent ages. Neurochem. Res. 2007;32:959\u2013964. doi:\n10.1007/s11064-006-9245-1. [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n55\\. Zugno A.I., Pereira L.O., Mattos C., Scherer E.B.S., Netto C.A., Wyse\nA.T.S. Guanidinoacetate administration increases acetylcholinesterase activity\nin striatum of rats and impairs retention of an inhibitory avoidance task.\nMetab. Brain Dis. 2008;23:189\u2013198. doi: 10.1007/s11011-008-9085-6. [PubMed]\n[CrossRef] [Google Scholar] [Ref list]\n\n56\\. Zugno A.I., Stefanello F.M., Scherer E.B.S., Mattos C., Pederzolli C.D.,\nAndrade V.M., Wannmacher C.M.D., Wajner M., Dutra-Filho C.S., Wyse A.T.S.\nGuanidinoacetate decreases antioxidant defenses and total protein sulfhydryl\ncontent in striatum of rats. Neurochem. Res. 2008;33:1804\u20131810. doi:\n10.1007/s11064-008-9636-6. [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n57\\. Ostojic S.M., Ostojic J. Dietary guanidinoacetic acid does not accumulate\nin the brain of healthy men. Eur. J. Nutr. 2018;57:3003\u20133005. doi:\n10.1007/s00394-017-1600-2. [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n58\\. Gillessen T., Budd S.L., Lipton S.A. Excitatory amino acid neurotoxicity.\nAdv. Exp. Med. Biol. 2002;513:3\u201340. doi: 10.1007/978-1-4615-0123-7_1. [PubMed]\n[CrossRef] [Google Scholar] [Ref list]\n\n59\\. Bender A., Klopstock T. Creatine for neuroprotection in neurodegenerative\ndisease: End of story? Amin. Acids. 2016;48:1929\u20131940. doi:\n10.1007/s00726-015-2165-0. [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n60\\. Mercimek-Andrews S., Salomons G.S. Creatine Deficiency Syndromes. Inborn\nMetab. Dis. Diagn. Treat. 2015:239\u2013247. [Google Scholar] [Ref list]\n\n61\\. Kaldis P., Hemmer W., Zanolla E., Holtzman D., Wallimann T. \u201cHot spots\u201d\nof creatine kinase localization in brain: Cerebellum, hippocampus and choroid\nplexus. Dev. Neurosci. 1996;18:542\u2013554. doi: 10.1159/000111452. [PubMed]\n[CrossRef] [Google Scholar] [Ref list]\n\n62\\. Borchio L., MacHek S.B., MacHado M. Supplemental creatine monohydrate\nloading improves cognitive function in experienced mountain bikers. J. Sports\nMed. Phys. Fit. 2020;60:1168\u20131170. doi: 10.23736/S0022-4707.20.10589-9.\n[PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n63\\. Benton D., Donohoe R. The influence of creatine supplementation on the\ncognitive functioning of vegetarians and omnivores. Br. J. Nutr.\n2011;105:1100\u20131105. doi: 10.1017/S0007114510004733. [PubMed] [CrossRef]\n[Google Scholar] [Ref list]\n\n64\\. McMorris T., Mielcarz G., Harris R., Swain J., Howard A. Creatine\nsupplementation and cognitive performance in elderly individuals.\nNeuropsychol. Dev. Cogn. B. Aging. Neuropsychol. Cogn. 2007;14:517\u2013528. doi:\n10.1080/13825580600788100. [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n65\\. Hammett S.T., Wall M.B., Edwards T.C., Smith A.T. Dietary supplementation\nof creatine monohydrate reduces the human fMRI BOLD signal. Neurosci. Lett.\n2010;479:201\u2013205. doi: 10.1016/j.neulet.2010.05.054. [PubMed] [CrossRef]\n[Google Scholar] [Ref list]\n\n66\\. Ling J., Kritikos M., Tiplady B. Cognitive effects of creatine ethyl\nester supplementation. Behav. Pharmacol. 2009;20:673\u2013679. doi:\n10.1097/FBP.0b013e3283323c2a. [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n67\\. McMorris T., Harris R.C., Howard A.N., Langridge G., Hall B., Corbett J.,\nDicks M., Hodgson C. Creatine supplementation, sleep deprivation, cortisol,\nmelatonin and behavior. Physiol. Behav. 2007;90:21\u201328. doi:\n10.1016/j.physbeh.2006.08.024. [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n68\\. McMorris T., Harris R.C., Swain J., Corbett J., Collard K., Dyson R.J.,\nDye L., Hodgson C., Draper N. Effect of creatine supplementation and sleep\ndeprivation, with mild exercise, on cognitive and psychomotor performance,\nmood state, and plasma concentrations of catecholamines and cortisol.\nPsychopharmacology. 2006;185:93\u2013103. doi: 10.1007/s00213-005-0269-z. [PubMed]\n[CrossRef] [Google Scholar] [Ref list]\n\n69\\. Smolarek A.C., Mcanulty S.R., Ferreira L.H., Cordeiro G.R., Alessi A.,\nRebesco D.B., Honorato I.C., Laat E.F., Mascarenhas L.P., Souza-Junior T.P.,\net al. Effect of 16 Weeks of Strength Training and Creatine Supplementation on\nStrength and Cognition in Older Adults: A Pilot Study. J. Exerc. Physiol.\n2020;23:88\u201394. [Google Scholar] [Ref list]\n\n70\\. VAN Cutsem J., Roelands B., Pluym B., Tassignon B., Verschueren J., DE\nPauw K., Meeusen R. Can Creatine Combat the Mental Fatigue-associated Decrease\nin Visuomotor Skills? Med. Sci. Sports Exerc. 2020;52:120\u2013130. doi:\n10.1249/MSS.0000000000002122. [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n71\\. Watanabe A., Kato N., Kato T. Effects of creatine on mental fatigue and\ncerebral hemoglobin oxygenation. Neurosci. Res. 2002;42:279\u2013285. doi:\n10.1016/S0168-0102(02)00007-X. [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n72\\. Pires L.A.M., Forbes S.C., Candow D.G., Machado M. Creatine\nsupplementation on cognitive performance following Creatine supplementation on\ncognitive performance following exercise in female Muay Thai athletes exercise\nin female Muay Thai athletes. J. Soc. NeuroSports. 2020;1:6. [Google Scholar]\n[Ref list]\n\n73\\. Rawson E.S., Lieberman H.R., Walsh T.M., Zuber S.M., Harhart J.M.,\nMatthews T.C. Creatine supplementation does not improve cognitive function in\nyoung adults. Physiol. Behav. 2008;95:130\u2013134. doi:\n10.1016/j.physbeh.2008.05.009. [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n74\\. Alves C.R.R., Filho C.A.A.M., Benatti F.B., Brucki S., Pereira R.M.R., de\nS\u00e3o Pinto A.L., Lima F.R., Roschel H., Gualano B. Creatine supplementation\nassociated or not with strength training upon emotional and cognitive measures\nin older women: A randomized double-blind study. PLoS ONE. 2013;8:e76301. doi:\n10.1371/journal.pone.0076301. [PMC free article] [PubMed] [CrossRef] [Google\nScholar] [Ref list]\n\n75\\. Rae C., Digney A.L., McEwan S.R., Bates T.C. Oral creatine monohydrate\nsupplementation improves brain performance: A double-blind, placebo-\ncontrolled, cross-over trial. Proc. R. Soc. B Biol. Sci. 2003;270:2147. doi:\n10.1098/rspb.2003.2492. [PMC free article] [PubMed] [CrossRef] [Google\nScholar] [Ref list]\n\n76\\. Harmon K.K., Stout J.R., Fukuda D.H., Pabian P.S., Rawson E.S., Stock\nM.S. The Application of Creatine Supplementation in Medical Rehabilitation.\nNutrients. 2021;13:1825. doi: 10.3390/nu13061825. [PMC free article] [PubMed]\n[CrossRef] [Google Scholar] [Ref list]\n\n77\\. Gualano B., Artioli G.G., Poortmans J.R., Lancha Junior A.H. Exploring\nthe therapeutic role of creatine supplementation. Amino Acids. 2010;38:31\u201344.\ndoi: 10.1007/s00726-009-0263-6. [PubMed] [CrossRef] [Google Scholar] [Ref\nlist]\n\n78\\. Klopstock T., Elstner M., Bender A. Creatine in mouse models of\nneurodegeneration and aging. Amino Acids. 2011;40:1297\u20131303. doi:\n10.1007/s00726-011-0850-1. [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n79\\. Xu C.J., Klunk W.E., Kanfe J.N., Xiong Q., Miller G., Pettegrew J.W.\nPhosphocreatine-dependent glutamate uptake by synaptic vesicles. A comparison\nwith atp-dependent glutamate uptake. J. Biol. Chem. 1996;271:13435\u201313440. doi:\n10.1074/jbc.271.23.13435. [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n80\\. Beal M.F. Neuroprotective effects of creatine. Amino Acids.\n2011;40:1305\u20131313. doi: 10.1007/s00726-011-0851-0. [PubMed] [CrossRef] [Google\nScholar] [Ref list]\n\n81\\. Mazzini L., Balzarini C., Colombo R., Mora G., Pastore I., De Ambrogio\nR., Caligari M. Effects of creatine supplementation on exercise performance\nand muscular strength in amyotrophic lateral sclerosis: Preliminary results.\nJ. Neurol. Sci. 2001;191:139\u2013144. doi: 10.1016/S0022-510X(01)00611-6. [PubMed]\n[CrossRef] [Google Scholar] [Ref list]\n\n82\\. Groeneveld G.J., Veldink J.H., Van der Tweel I., Kalmijn S., Beijer C.,\nDe Visser M., Wokke J.H.J., Franssen H., Van den Berg L.H. A randomized\nsequential trial of creatine in amyotrophic lateral sclerosis. Ann. Neurol.\n2003;53:437\u2013445. doi: 10.1002/ana.10554. [PubMed] [CrossRef] [Google Scholar]\n[Ref list]\n\n83\\. Rosenfeld J., King R.M., Jackson C.E., Bedlack R.S., Barohn R.J., Dick\nA., Phillips L.H., Chapin J., Gelinas D.F., Lou J.S. Creatine monohydrate in\nALS: Effects on strength, fatigue, respiratory status and ALSFRS. Amyotroph.\nLateral Scler. 2008;9:266\u2013272. doi: 10.1080/17482960802028890. [PMC free\narticle] [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n84\\. Shefner J.M., Cudkowicz M.E., Schoenfeld D., Conrad T., Taft J., Chilton\nM., Urbinelli L., Qureshi M., Zhang H., Pestronk A., et al. A clinical trial\nof creatine in ALS. Neurology. 2004;63:1656\u20131661. doi:\n10.1212/01.WNL.0000142992.81995.F0. [PubMed] [CrossRef] [Google Scholar] [Ref\nlist]\n\n85\\. Passamano L., Taglia A., Palladino A., Viggiano E., D\u2019Ambrosio P.,\nScutifero M., Cecio M.R., Torre V., De Luca F., Picillo E., et al. Improvement\nof survival in DuchenneMuscular Dystrophy: Retrospective analysisof 835\npatients. Acta Myol. 2012;31:125. [PMC free article] [PubMed] [Google Scholar]\n[Ref list]\n\n86\\. Louis M., Lebacq J., Poortmans J.R., Belpaire-Dethiou M.-C., Devogelaer\nJ.-P., Van Hecke P., Goubel F., Francaux M. Beneficial effects of creatine\nsupplementation in dystrophic patients. Muscle Nerve. 2003;27:604\u2013610. doi:\n10.1002/mus.10355. [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n87\\. Tarnopolsky M.A., Mahoney D.J., Vajsar J., Rodriguez C., Doherty T.J.,\nRoy B.D., Biggar D. Creatine monohydrate enhances strength and body\ncomposition in Duchenne muscular dystrophy. Neurology. 2004;62:1771\u20131777. doi:\n10.1212/01.WNL.0000125178.18862.9D. [PubMed] [CrossRef] [Google Scholar] [Ref\nlist]\n\n88\\. Escolar D., Buyse G., Henricson E., Leshner R., Florence J., Mayhew J.,\nTesi-Rocha C., Gorni K., Pasquali L., Patel K., et al. CINRG randomized\ncontrolled trial of creatine and glutamine in Duchenne muscular dystrophy.\nAnn. Neurol. 2005;58:151\u2013155. doi: 10.1002/ana.20523. [PubMed] [CrossRef]\n[Google Scholar] [Ref list]\n\n89\\. Hersch S.M., Gevorkian S., Marder K., Moskowitz C., Feigin A., Cox M.,\nComo P., Zimmerman C., Lin M., Zhang L., et al. Creatine in Huntington disease\nis safe, tolerable, bioavailable in brain and reduces serum 8OH2\u2019dG.\nNeurology. 2006;66:250\u2013252. doi: 10.1212/01.wnl.0000194318.74946.b6. [PubMed]\n[CrossRef] [Google Scholar] [Ref list]\n\n90\\. Tabrizi S.J., Blamire A.M., Manners D.N., Rajagopalan B., Styles P.,\nSchapira A.H.V., Warner T.T. High-dose creatine therapy for Huntington\ndisease: A 2-year clinical and MRS study. Neurology. 2005;64:1655\u20131656. doi:\n10.1212/01.WNL.0000160388.96242.77. [PubMed] [CrossRef] [Google Scholar] [Ref\nlist]\n\n91\\. Tabrizi S.J., Blamire A.M., Manners D.N., Rajagopalan B., Styles P.,\nSchapira A.H.V., Warner T.T. Creatine therapy for Huntington\u2019s disease:\nClinical and MRS findings in a 1-year pilot study. Neurology. 2003;61:141\u2013142.\ndoi: 10.1212/01.WNL.0000070186.97463.A7. [PubMed] [CrossRef] [Google Scholar]\n[Ref list]\n\n92\\. Verbessem P., Lemiere J., Eijnde B.O., Swinnen S., Vanhees L., Van\nLeemputte M., Hespel P., Dom R. Creatine supplementation in Huntington\u2019s\ndisease: A placebo-controlled pilot trial. Neurology. 2003;61:925\u2013930. doi:\n10.1212/01.WNL.0000090629.40891.4B. [PubMed] [CrossRef] [Google Scholar] [Ref\nlist]\n\n93\\. Bender A., Auer D.P., Merl T., Reilmann R., Saemann P., Yassouridis A.,\nBender J., Weindl A., Dose M., Gasser T., et al. Creatine supplementation\nlowers brain glutamate levels in Huntington\u2019s disease. J. Neurol.\n2005;252:36\u201341. doi: 10.1007/s00415-005-0595-4. [PubMed] [CrossRef] [Google\nScholar] [Ref list]\n\n94\\. Hersch S.M., Schifitto G., Oakes D., Bredlau A.L., Meyers C.M., Nahin R.,\nRosas H.D. The CREST-E study of creatine for Huntington disease: A randomized\ncontrolled trial. Neurology. 2017;89:594\u2013601. doi:\n10.1212/WNL.0000000000004209. [PMC free article] [PubMed] [CrossRef] [Google\nScholar] [Ref list]\n\n95\\. Lambert C.P., Archer R.L., Carrithers J.A., Fink W.J., Evans W.J., Trappe\nT.A. Influence of creatine monohydrate ingestion on muscle metabolites and\nintense exercise capacity in individuals with multiple sclerosis. Arch. Phys.\nMed. Rehabil. 2003;84:1206\u20131210. doi: 10.1016/S0003-9993(03)00262-4. [PubMed]\n[CrossRef] [Google Scholar] [Ref list]\n\n96\\. Malin S.K., Cotugna N., Fang C.S. Effect of creatine supplementation on\nmuscle capacity in individuals with multiple sclerosis. J. Diet. Suppl.\n2008;5:20\u201332. doi: 10.1080/19390210802328974. [PubMed] [CrossRef] [Google\nScholar] [Ref list]\n\n97\\. Olanow C.W., Stern M.B., Sethi K. The scientific and clinical basis for\nthe treatment of Parkinson disease (2009) Neurology. 2009;72:S1\u2013S136. doi:\n10.1212/WNL.0b013e3181a1d44c. [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n98\\. Yang L., Calingasan N.Y., Wille E.J., Cormier K., Smith K., Ferrante\nR.J., Flint Beal M. Combination therapy with coenzyme Q10 and creatine\nproduces additive neuroprotective effects in models of Parkinson\u2019s and\nHuntington\u2019s diseases. J. Neurochem. 2009;109:1427\u20131439. doi:\n10.1111/j.1471-4159.2009.06074.x. [PMC free article] [PubMed] [CrossRef]\n[Google Scholar] [Ref list]\n\n99\\. Bender A., Koch W., Elstner M., Schombacher Y., Bender J., Moeschl M.,\nGekeler F., M\u00fcller-Myhsok B., Gasser T., Tatsch K., et al. Creatine\nsupplementation in Parkinson disease: A placebo-controlled randomized pilot\ntrial. Neurology. 2006;67:1262\u20131264. doi: 10.1212/01.wnl.0000238518.34389.12.\n[PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n100\\. Hass C.J., Collins M.A., Juncos J.L. Resistance training with creatine\nmonohydrate improves upper-body strength in patients with Parkinson disease: A\nrandomized trial. Neurorehabil. Neural Repair. 2007;21:107\u2013115. doi:\n10.1177/1545968306293449. [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n101\\. Kieburtz K., Tilley B.C., Elm J.J., Babcock D., Hauser R., Ross G.W.,\nAugustine A.H., Augustine E.U., Aminoff M.J., Bodis-Wollner I.G., et al.\nEffect of creatine monohydrate on clinical progression in patients with\nParkinson disease: A randomized clinical trial. JAMA. 2015;313:584\u2013593. doi:\n10.1001/jama.2015.120. [PMC free article] [PubMed] [CrossRef] [Google Scholar]\n[Ref list]\n\n102\\. Kessler R.C., Wai T.C., Demler O., Walters E.E. Prevalence, severity,\nand comorbidity of 12-month DSM-IV disorders in the National Comorbidity\nSurvey Replication. Arch. Gen. Psychiatry. 2005;62:617\u2013627. doi:\n10.1001/archpsyc.62.6.617. [PMC free article] [PubMed] [CrossRef] [Google\nScholar] [Ref list]\n\n103\\. Palay J., Taillieu T.L., Afifi T.O., Turner S., Bolton J.M., Enns M.W.,\nSmith M., Lesage A., Bakal J.A., Rush B., et al. Prevalence of Mental\nDisorders and Suicidality in Canadian Provinces. Can. J. Psychiatry.\n2019;64:761\u2013769. doi: 10.1177/0706743719878987. [PMC free article] [PubMed]\n[CrossRef] [Google Scholar] [Ref list]\n\n104\\. Masand P.S. Tolerability and adherence issues in antidepressant therapy.\nClin. Ther. 2003;25:2289\u20132304. doi: 10.1016/S0149-2918(03)80220-5. [PubMed]\n[CrossRef] [Google Scholar] [Ref list]\n\n105\\. Nemeroff C.B. Prevalence and management of treatment-resistant\ndepression. J. Clin. Psychiatry. 2007;68:17\u201325. doi: 10.4088/JCP.0707e17.\n[PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n106\\. Usala T., Clavenna A., Zuddas A., Bonati M. Randomised controlled trials\nof selective serotonin reuptake inhibitors in treating depression in children\nand adolescents: A systematic review and meta-analysis. Eur.\nNeuropsychopharmacol. 2008;18:62\u201373. doi: 10.1016/j.euroneuro.2007.06.001.\n[PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n107\\. Doran C.M., Kinchin I. A review of the economic impact of mental\nillness. Aust. Heal. Rev. 2019;43:43\u201348. doi: 10.1071/AH16115. [PubMed]\n[CrossRef] [Google Scholar] [Ref list]\n\n108\\. Fons C., Campistol J. Creatine Defects and Central Nervous System.\nSemin. Pediatr. Neurol. 2016;23:285\u2013289. doi: 10.1016/j.spen.2016.11.003.\n[PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n109\\. Faulkner P., Paioni S.L., Kozhuharova P., Orlov N., Lythgoe D.J., Daniju\nY., Morgenroth E., Barker H., Allen P. Relationship between depression,\nprefrontal creatine and grey matter volume. J. Psychopharmacol.\n2021;35:1464\u20131472. doi: 10.1177/02698811211050550. [PMC free article] [PubMed]\n[CrossRef] [Google Scholar] [Ref list]\n\n110\\. Allen P.J., D\u2019Anci K.E., Kanarek R.B., Renshaw P.F. Sex-specific\nantidepressant effects of dietary creatine with and without sub-acute\nfluoxetine in rats. Pharmacol. Biochem. Behav. 2012;101:588\u2013601. doi:\n10.1016/j.pbb.2012.03.005. [PMC free article] [PubMed] [CrossRef] [Google\nScholar] [Ref list]\n\n111\\. Bakian A.V., Huber R.S., Scholl L., Renshaw P.F., Kondo D. Dietary\ncreatine intake and depression risk among U.S. adults. Transl. Psychiatry.\n2020;10:52. doi: 10.1038/s41398-020-0741-x. [PMC free article] [PubMed]\n[CrossRef] [Google Scholar] [Ref list]\n\n112\\. Allen P.J., D\u2019Anci K.E., Kanarek R.B., Renshaw P.F. Chronic creatine\nsupplementation alters depression-like behavior in rodents in a sex-dependent\nmanner. Neuropsychopharmacology. 2010;35:534\u2013546. doi: 10.1038/npp.2009.160.\n[PMC free article] [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n113\\. Allen P.J., Debold J.F., Rios M., Kanarek R.B. Chronic high-dose\ncreatine has opposing effects on depression-related gene expression and\nbehavior in intact and sex hormone-treated gonadectomized male and female\nrats. Pharmacol. Biochem. Behav. 2015;130:22\u201333. doi:\n10.1016/j.pbb.2014.12.014. [PMC free article] [PubMed] [CrossRef] [Google\nScholar] [Ref list]\n\n114\\. Kanekar S., Ettaro R., Hoffman M.D., Ombach H.J., Brown J., Lynch C.,\nSheth C.S., Renshaw P.F. Sex-Based Impact of Creatine Supplementation on\nDepressive Symptoms, Brain Serotonin and SSRI Efficacy in an Animal Model of\nTreatment-Resistant Depression. Int. J. Mol. Sci. 2021;22:8195. doi:\n10.3390/ijms22158195. [PMC free article] [PubMed] [CrossRef] [Google Scholar]\n[Ref list]\n\n115\\. Okwuofu E.O., Ogundepo G.E., Akhigbemen A.M., Abiola A.L., Ozolua R.I.,\nIgbe I., Chinazamoku O. Creatine attenuates seizure severity, anxiety and\ndepressive-like behaviors in pentylenetetrazole kindled mice. Metab. Brain\nDis. 2021;36:571\u2013579. doi: 10.1007/s11011-021-00684-w. [PubMed] [CrossRef]\n[Google Scholar] [Ref list]\n\n116\\. Rosa J.M., Pazini F.L., Cunha M.P., Colla A.R.S., Manosso L.M., Mancini\nG., Souza A.C.G., de Bem A.F., Prediger R.D., Rodrigues A.L.S. Antidepressant\neffects of creatine on amyloid \u03b2 1-40-treated mice: The role of GSK-3\u03b2/Nrf 2\npathway. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2018;86:270\u2013278. doi:\n10.1016/j.pnpbp.2018.05.001. [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n###### Other Formats\n\n  * PDF (596K)\n\n###### Actions\n\n  * Add to Collections\n\n###### Share\n\n  * Permalink\n\n###### RESOURCES\n\nCite\n\nDownload .nbib .nbib\n\nFollow NCBI\n\nConnect with NLM\n\nNational Library of Medicine 8600 Rockville Pike Bethesda, MD 20894\n\nWeb Policies FOIA HHS Vulnerability Disclosure\n\nHelp Accessibility Careers\n\nExternal link. Please review our privacy policy.\n\n", "frontpage": false}
